<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2842</article-id>
         <article-id pub-id-type="publisher-id">2842</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Oncology</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Onkologija</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Review article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Pregledni znanstveni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Onkologija</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Humane celične linije raka dojk</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Human breast cancer cell lines</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Humane celične linije raka dojk</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Skok</surname>
                  <given-names>Kristijan</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Maver</surname>
                  <given-names>Uroš</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Gradišnik</surname>
                  <given-names>Lidija</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Kavalar</surname>
                  <given-names>Rajko</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Sobočan</surname>
                  <given-names>Monika</given-names>
               </name>
               <xref ref-type="aff" rid="aff3">3</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Takač</surname>
                  <given-names>Iztok</given-names>
               </name>
               <xref ref-type="aff" rid="aff3">3</xref>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Inštitut za biomedicinske vede, Medicinska fakulteta, Univerza v Mariboru, Maribor, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Institute of biomedical sciences, Faculty of medicine, University of Maribor, Maribor, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff2">
            <aff xml:lang="sl">
               <label>2</label>
               <institution>Oddelek za patologijo, Univerzitetni klinični center Maribor, Maribor, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>2</label>
               <institution>Department of Patology, University Medical Centre Maribor, Maribor, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff3">
            <aff xml:lang="sl">
               <label>3</label>
               <institution>Klinika za ginekologijo in perinatologijo, Univerzitetni klinični center Maribor, Maribor, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>3</label>
               <institution>Division of Gyneacology and Perinatology, University Medical Centre Maribor, Maribor, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Kristijan Skok, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>10</month>
            <year>2019</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>10</month>
            <year>2019</year>
         </pub-date>
         <volume>88</volume>
         <issue>9–10</issue>
         <fpage>427</fpage>
         <lpage>43</lpage>
         <history>
            <date date-type="received">
               <day>10</day>
               <month>5</month>
               <year>2018</year>
            </date>
            <date date-type="accepted">
               <day>7</day>
               <month>1</month>
               <year>2019</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2019, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2019, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2019</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Rak dojk je drugi najpogostejši rak na svetu in daleč najpogostejše pri ženskah, tako v razvitem svetu kot tudi v državah v razvoju. Uvršča se na peto mesto po vzroku smrti zaradi raka. V Sloveniji beležimo letno približno 1.310 novih primerov raka dojk. Ločimo več podtipov raka dojk, ki jih lahko delimo na podlagi histopatološke ter molekularne delitve oz. intrinzičnih lastnosti. V pomoč pri raziskovanju posameznih podtipov raka dojk služijo tudi celične linije. Prvo celično linijo raka dojk so ustvarili leta 1958 in jo poimenovali BT-20 (1958, Lasfargues in Ozzello). Število celičnih linij je v zadnjih letih drastično naraslo. Pogosto uporabljene celične linije so MCF7, T47D in MDAMB231. MCF7 in T47D sta vrsti luminalnega tipa A (ER+/PR+/HER2-) in MDAMB231 je trojno negativna (ER-/PR-/HER2-). Na področju celičnih linij so vidne nedoslednosti glede poimenovanja kot tudi gojenja. Prav tako je tudi vprašljiva ponovljivost gojenja v različnih laboratorijih ali pogojih, kjer celične linije lahko razvijejo drugačne lastnosti (npr. dediferenciacija, sprememba fenotipa, mutacije). V literaturi so vidni primeri različne kategorizacije iste celične linije v edinstvene skupine na podlagi drugačnega molekularnega in morfološkega opisa. Avtorji menijo, da je zato potreben pregled nad literaturo in opis trenutno znanega. V prispevku se osredinjajo na tematiko celičnih linij raka dojk, njihovo nomenklaturo, delitev, gojenje in uporabnost.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Breast cancer is the second most common cancer worldwide and ranked first in incidence in women living either in developed or developing countries. It is ranked as the fifth common cause of cancer death. Annually, there are 1310 new cases of breast cancer in Slovenia. There are many types of breast cancer that we can differentiate based on their histopathology and molecular i.e. intrinsic properties. Breast cancer cell lines play a significant role in breast cancer research and analysis of different subtypes. The first breast cancer cell line was established in 1958 and named BT-20 (1958, Lasfargues in Ozzello). In recent years the number of cell lines has drastically increased. Commonly used breast cancer cell lines are MCF7, T47D and MDAMB231. The MCF7 and T47D cell lines are luminal A type (ER+/PR+/HER2-), whereas MDAMB231 is triple negative (ER-/PR-/HER2-). There are many inconsistencies in nomenclature and culturing of cell lines. Also, questionable is the consistency and repeatability of research in different laboratories or conditions, where cell lines could develop different traits (e.g. dedifferentiation, change of phenotype, mutations). There are examples of different categorisation into unique subtypes of the same cell lines in literature, based on different molecular and morphological descriptions. Therefore, the authors believe that there is a need for a literature review of the currently available information. The authors focused on breast cancer cell lines, their nomenclature, differentiation, culturing and usefulness.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>celične linije raka dojk</kwd>
            <kwd>rak dojk</kwd>
            <kwd>trojno negativni rak dojk</kwd>
            <kwd>in vitro celične linije</kwd>
            <kwd>celična kultura</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>breast cancer cell lines</kwd>
            <kwd>breast cancer</kwd>
            <kwd>triple negative breast cancer</kwd>
            <kwd>in vitro cell lines</kwd>
            <kwd>cell culture</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Rak dojk (RD) je drugi najpogostejši rak na svetu in daleč najpogostejši pri ženskah, tako v razvitem svetu (incidenca 794.000 na leto) kot tudi v državah v razvoju, kjer je njegova incidenca še nekoliko višja (883.000 na leto). Na svetovni ravni se RD uvršča na peto mesto po vzroku smrti zaradi raka (522.000 smrti) (<xref ref-type="bibr" rid="b1">1</xref>). V Sloveniji beležimo letno približno 1.310 novih primerov RD in 380 smrtnih izidov letno (<xref ref-type="bibr" rid="b2">2</xref>). Od leta 1968 je najpogostejše mesto raka pri ženskah (20–25 % vseh primerov rakavih bolezni) (<xref ref-type="bibr" rid="b2">2</xref>).</p>
         <p>Ločimo več podtipov RD, ki jih lahko delimo na podlagi histopatološke ter molekularne delitve oz. intrinzičnih lastnosti. Eden teh podtipov je trojno negativni RD (TNRD), za katerega je značilna odsotnost hormonskih receptorjev za estrogene (ER), progesteron (PR) in izraženosti receptorjev za človeški epidermalni rastni faktor-2 (HER2). Napoved izida in stopnja preživetja sta v zahodnem svetu sorazmerno dobri, vendar je pri podtipu TNRD napoved izida najslabša, saj ta hitro napreduje, zaseva in je bolj agresiven (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b4">4</xref>). Prav zaradi tega imajo raziskave, ki želijo to vrsto raka podrobneje opredeliti, velik pomen. V sklopu teh raziskav je vedno več novih metod, ki se poslužujejo molekularnih ter drugih interdisciplinarnih pristopov. Eden prospektivnih pristopov raziskovanja RD so <italic>in vitro</italic> ter <italic>in vivo</italic> modeli (<xref ref-type="bibr" rid="b5">5</xref>-<xref ref-type="bibr" rid="b7">7</xref>). V prispevku se osredinjamo na pregled tematike RD ter <italic>in vitro</italic> metod gojenja celičnih linij (CL) RD z namenom razumeti razvoj CL RD za izboljšanje znanja in nato zdravljenja na področju RD.</p>
      </sec>
      <sec id="s2" sec-type="Klasifikacija malignih sprememb raka dojk">
         <label>2</label>
         <title>Klasifikacija malignih sprememb raka dojk</title>
         <p>RD lahko delimo na različne načine. V okviru standardne obravnave bolnic z RD se poleg histološke vrste tumorja določa še velikost tumorja, stopnja zrelosti (Gradus: Elston in Ellis), prisotnost ali odsotnost limfo-vaskularne infiltracije, prisotnost intraepitelne komponente, mikroskopski status robov, imunohistokemična izraženost hormonskih receptorjev (ER, PR), izraženost receptorjev za HER2 in pomnožitev gena HER2. Kot napovedni dejavnik se določa še proliferacijski indeks Ki67. Določajo se lahko še proteaze in genski podpis, ki so lahko v pomoč tudi pri odločanju o dodatnem, tj. dopolnilnem zdravljenju. Le-ti so tudi pomembni pri upoštevanju gojenja CL, kajti za uspešno gojenje določene CL je potrebno natančno poznati vrsto izvornega tkiva in njegove lastnosti (gojenje, uporaba primernega medija, karakterizacija) (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref>).</p>
         <sec id="s2.1" sec-type="Histopatološko razvrščanje">
            <label>2.1</label>
            <title>Histopatološko razvrščanje</title>
            <p>Primarni RD delimo na neinvazivne in invazivne oblike. Med neinvazivne prištevamo duktalni intraepitelni karcinom (DCIS) in lobularni intraepitelni karcinom (LCIS). Značilnost teh vrst raka je, da ne preraščajo bazalne membrane in ne zasevajo v oddaljene organe (<xref ref-type="bibr" rid="b8">8</xref>).</p>
            <p>Pogosteje se v dojki pojavlja invazivni rak. Najpogostejši nespecialni tip (NST) invazivnega karcinoma, ki predstavlja od 40–75 % vseh invazivnih RD in je pogosto pridružen DCIS. V skupino NST so vključeni še karcinomi mešanih tipov in redke oblike karcinomov, kot so pleomorfni rak, rak z osteoklastom podobnimi velikankami, rak s horiokarcinomskimi lastnostmi in rak z melanotičnimi lastnostmi.</p>
            <p>Drugi najpogostejši RD je invazivni lobularni karcinom (ILC), ki se pojavlja v nekoliko starejši populaciji žensk (57–65 let) in predstavlja 5–15 % vseh invazivnih vrst RD. ILC ni homogena oblika RD, saj ga tvorijo klasični, solidni in pleomorfni tip, tubulolobularna varianta ter mešana oblika prej naštetih tipov.</p>
            <p>Tubularni karcinom in kribriformni karcinom sta dve obliki RD, ki sta redki obliki RD (2 % in 0,3–4 %) in imata zelo dobro napoved izida.</p>
            <p>V skupino karcinomov z medularnimi lastnostmi spadajo klasični medularni karcinom, atipični medularni karcinom in invazivni karcinom NST z medularnimi lastnostmi. Značilnost klasičnega medularnega karcinoma, ki je redka oblika karcinoma (manj kot 1 % vseh RD), ima sorazmerno dober izid, ki naj bi bil odvisen od gostote limfoplazmocitnega infiltrata, ki je eno od diagnostičnih meril tumorja.</p>
            <p>Čiste oblike mucinoznega karcinoma je 2 % vseh RD in se običajno pojavlja pri ženskah, starih nad 55 let. Ima dobro 5-letno napoved preživetja in zelo nizko stopnjo lokalnih ponovitev.</p>
            <p>V skupino metaplastičnega karcinoma dojke spadajo ploščatocelični karcinom, vretenastocelični karcinom, karcinomi z mezenhimalno diferenciacijo, fibromatozi podobni metaplastični karcinom in adenoskvamozni karcinom nizke stopnje malignosti ter jih je 0,2–5 % vseh RD. Redkeje zasevajo v pazdušne bezgavke kot invazivni karcinom NST.</p>
            <p>Druge še redkejše oblike invazivnih RD so: mikropapilarni, slinavkam in kožnim adneksom podobni karcinomi, adenoidno cistični karcinom, karcinom z apokrino diferenciacijo, skupina karcinomov z nevroendokrino diferenciacijo, papilarni karcinom in vnetni karcinom (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref>).</p>
         </sec>
         <sec id="s2.2" sec-type="Intrinzično in molekularno razvrščanje">
            <label>2.2</label>
            <title>Intrinzično in molekularno razvrščanje</title>
            <p>Na podlagi profila genske izraženosti ločimo več podtipov RD. S pomočjo imunohistokemične in delimo RD glede na prisotnost/odsotnost ER in PR. S imunohistokemijo in <italic>in</italic>
               <italic> situ</italic> hibridizacije določamo čezmerno izraženost HER2 onkoproteina in/ali pomnoženost gena HER2 (<xref ref-type="bibr" rid="b9">9</xref>). Negativna receptorski in status HER2 sta značilna za TNRD (<xref ref-type="bibr" rid="b4">4</xref>).</p>
            <p>Z razvojem DNA mikromrež (<italic>angl.</italic> microarrays) se je gensko ekspresijsko profiliranje (GEP) zelo razširilo pri napovedi izida RD. Eden ključnih namenov je opredeliti bolnike z dovolj dobro napovedjo izida, ki bi omogočala opustitev kemoterapije. Pionirsko raziskavo na tem področju so naredili Sørlie in sod., ki so v svoji raziskavi ugotovili značilen molekularni profil RD s fragmenti 456cDNA (<xref ref-type="bibr" rid="b10">10</xref>). Na podlagi tega so RD klasificirali v 5 različnih intrinzičnih podtipov z značilnim kliničnim potekom ter izidom (luminalni tip A, luminalni tip B, tumorji s pomnoženim genom HER2, tj. s pozitivnim HER2 statusom, bazalni in normalnemu epitelu-podobni tumorji; (<italic>angl.</italic> normal epithelial-like) (<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b12">12</xref>). Vsak podtip ima svojo napoved izida in odgovor na zdravljenje. Podtip luminalni A (RD, pri katerem je proliferacijski indeks, ki je odraz Ki67 imunoreaktivnost, manjši kot 15 %) in podtip B (RD, pri katerem je proliferacijski indeks, ki je odraz Ki67 imunoreaktivnost, večji kot 15 %) sta podtipa, ki sta odzivna na hormonsko zdravljenje. Skupina RD s pozitivnim statusom HER2 je primerna za zdravljenje s trastuzumabom. Bazalni fenotip je opisan kot TNRD zato, ker je zanj značilen negativnim hormonski (ER in PR) in negativni status HER2. Čeprav obstajajo podobnosti med bazalnim tipom RD in TNRD, teh dveh kategorij RD ne velja enačiti, kajti v skupino TNRD lahko prištevamo še druge podtipe (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            <p>Kljub številnim poimenovanjem in različnemu številu kategorij spada RD večinoma v 3 glavne intrinzične skupine (t. i. luminalni, HER2-pozitiven in TNRD fenotipski tumorji, ki so najbolj heterogeni in so večinoma bazalnega podtipa). Prikaz delitve tumorjev je v <table-wrap position="float" id="table1">
                  <label>Tabela 1:</label>
                  <caption>
                     <p> Prikaz delitve RD na podskupine.</p>
                  </caption>
                  <table>
                     <colgroup>
                        <col/>
                        <col/>
                        <col/>
                        <col/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th>Intrinzični podtip</th>
                           <th>IHC status</th>
                           <th>Gradus</th>
                           <th>Prevalenca</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td>Luminali tip A</td>
                           <td>(ER+, PR+), HER2-, KI67- (&lt; 15 %)</td>
                           <td align="right">1/2</td>
                           <td align="right">23,7 %</td>
                        </tr>
                        <tr>
                           <td>Luminali tip B</td>
                           <td>
                              <p>(ER+,PR+), HER2-, KI67+(&gt; 15 %)</p>
                              <p>(ER+, PR-), HER2-, KI67+(&gt; 15 %)</p>
                           </td>
                           <td align="right">2/3</td>
                           <td>
                              <p>38,8 %</p>
                              <p>14 %</p>
                           </td>
                        </tr>
                        <tr>
                           <td>HER2</td>
                           <td>(ER-, PR-), HER2+</td>
                           <td align="right">2/3</td>
                           <td align="right">11,2 %</td>
                        </tr>
                        <tr>
                           <td>Bazalni</td>
                           <td>(ER-,PR-), HER2-, bazalni označevalci+</td>
                           <td align="right">3</td>
                           <td align="right">12,3 %</td>
                        </tr>
                        <tr>
                           <td>Normalnemu-podoben</td>
                           <td>(ER+,PR+), HER2-, KI67- (&lt; 15 %)</td>
                           <td align="right">1/2/3</td>
                           <td align="right">7,8 %</td>
                        </tr>
                     </tbody>
                  </table>
                  <table-wrap-foot>
                     <p>Legenda: IHC – Imunohistokemični status, ER – estrogenski receptor, PR – progesteronski receptor. Mejna vrednost za Ki67 je 15 %. Tabela 1 je povzeta po Dai in sod. (<xref ref-type="bibr" rid="b15">15</xref>), uporabljeno z licenco CC BY-NC 4.0.</p>
                  </table-wrap-foot>
               </table-wrap>
               <xref ref-type="table" rid="table1">Tabeli 1</xref> (<xref ref-type="bibr" rid="b13">13</xref>-<xref ref-type="bibr" rid="b15">15</xref>).</p>
         </sec>
      </sec>
      <sec id="s3" sec-type="Celične linije">
         <label>3</label>
         <title>Celične linije</title>
         <p>Pomemben delež novih dognanj o RD je rezultat <italic>in vitro</italic> in <italic>in vivo</italic> raziskav na CL (<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b16">16</xref>,<xref ref-type="bibr" rid="b17">17</xref>). Pogosto uporabljene CL so MCF7, T47D in MDAMB231 (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b18">18</xref>). Njihove značilnosti so: MCF-7 – CL RD tipa LA je bila izolirana leta 1970 od 69-letne belke; T47D CL tipa LA je bila izolirana iz plevralnega izliva duktalnega karcinoma dojke 54-letne ženske; MDAMB231 CL RD tipa TNRD bazalni podtip B (TNRD-B) je bila izolirana iz adenokarcinoma 51-letne ženske; BT-20 CL RD tipa TNRD bazalni podtip A (TNRD-A) pa je bila izolirana iz RD 74-letne ženske leta 1958.</p>
         <sec id="s3.1"
              sec-type="Nomenklatura celičnih linij in njihovo poimenovanje">
            <label>3.1</label>
            <title>Nomenklatura celičnih linij in njihovo poimenovanje</title>
            <p>Prvo humano CL je osamil George Gey pred več kot šestdesetimi leti (1951) v laboratoriju v Baltimoru. Poimenovana je bila po bolnici, katere tkivo raka materničnega vratu so uporabili. Bolnici je bilo ime Henrietta Lacks in CL so poimenovali HeLa (<xref ref-type="bibr" rid="b19">19</xref>).</p>
            <p>Prva CL RD je bila ustvarjena leta 1958 in poimenovana BT-20 (<xref ref-type="bibr" rid="b20">20</xref>). Po dvajsetih letih je prišlo do naslednjega preboja in CL so postale bolj dostopne (<xref ref-type="bibr" rid="b21">21</xref>,<xref ref-type="bibr" rid="b22">22</xref>). Izšla je serija CL MDA (M. D. Anderson Hospital and Tumor Institute). Leta 1973 so v Michigan Cancer Foundation ustvarili linijo MCF-7, ki je še dandanes ena najpogosteje uporabljenih na svetu. Za njo je značilna velika občutljivost ER, kar omogoča raziskave in modele za raziskovanje hormonske odzivnosti (<xref ref-type="bibr" rid="b23">23</xref>). Poimenovanje CL večinoma ni vezano na fenotipske značilnosti, ampak kako in kje so bile ustvarjene (laboratorij, bolnik, izolacije iz subkulture ipd.). Nekaj primerov takšnega poimenovanja so: serija HCC, ki je bila izolirana v Hamon Cancer Centre; MDA serija, poimenovana po M. D. Anderson Hospital and Tumor Institute; serija MHT je znana po številnih subkultivacijah pod različnimi pogoji (npr. P53 mutacije, MYC pomnožitev, EGF-neodvisnost ipd.) itd. (<xref ref-type="bibr" rid="b5">5</xref>). Do pred kratkim za poimenovanje CL še ni bilo posebnih priporočil in so se lahko poimenovale tudi po znanstveniku, ki jih je ustvaril. Z novimi priporočili se bo temu moč izogniti in zagotoviti lažje razumevanje in raziskovanje na tem področju (<xref ref-type="bibr" rid="b24">24</xref>).</p>
            <p>V nadaljevanju povzemamo in navajamo nekatere pomembnejše točke in usmeritve pri poimenovanju CL iz trenutno aktualnih priporočil (<xref ref-type="bibr" rid="b24">24</xref>). Poimenovanje s kratkim imenom ali zgolj eno črko je neprimerno in onemogoča iskanje in razpoznavnost na spletu. Glavna priporočila so:</p>
            <list>
               <list-item>
                  <label>1.</label>
                  <p>ne sme se uporabiti ime donorja ali drugih osebnih podatkov (npr. letnica rojstva), ki bi ogrozili anonimnost bolnika;</p>
               </list-item>
               <list-item>
                  <label>2.</label>
                  <p>ime CL mora vsebovati vsaj 6 znakov, vendar ne splošno uporabljenega termina (npr. glioma);</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>znaki zapisa morajo biti takšni, da ne povzročajo težav pri indeksiranju ali računalniškem iskanju (npr. posebni znaki, pismenke ipd.), znaki se lahko zapišejo z veliko ali malo, arabske številke, pomišljaji in podčrtaji pa so primerni;</p>
               </list-item>
               <list-item>
                  <label>4.</label>
                  <p>ne sme se uporabiti presledkov, zvezdic, nadpisanih ali podpisanih znakov, poševnic, vprašajev, klicajev, presledkov, vejic, podpičij, grških črk ali drugih simbolov;</p>
               </list-item>
               <list-item>
                  <label>5.</label>
                  <p>podano ime mora biti edinstveno.</p>
               </list-item>
            </list>
            <p>Preverba se opravi z iskanjem po spletu (Google, PubMed, ipd.) ter spletne strani Cellosaurus (web.expasy.org/cellosaurus). Pri iskanju se morajo preveriti tudi različice imena (npr. T406, T 406, T-406) in potencialno skrajšane oblike (npr. NCI-H420 ali H420) (<xref ref-type="bibr" rid="b24">24</xref>).</p>
            <p>Za embrionalne matične celice in inducirane pluripotentne matične celice se je že uveljavila standardizirana nomenklatura. Priporočeni slog poimenovanja za druge linije je:</p>
            <p>1.priporoča se uporaba določilnika izvora (<italic>angl.</italic> Origin identifier), ki se nanaša na inštitut ali laboratorij, kjer so CL vzgojili (npr. SK-Sloan Kettering, WI za Wistar Institute, MFUM – Medical Faculty, University of Maribor);</p>
            <list>
               <list-item>
                  <label>2.</label>
                  <p>uporaba označevalca za serijo ali tkivo (npr. GI-glioma, Lu-lung, Br-breast);</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>uporaba številke za identifikacijo specifične CL (npr. številka, odčitana iz posode, v kateri se je nahajalo tkivo);</p>
               </list-item>
               <list-item>
                  <label>4.</label>
                  <p>dodatna številka, večinoma alfanumerična kombinacija dveh znakov, bi določila podvrsto, klon ali transformirane kulture (<xref ref-type="bibr" rid="b24">24</xref>).</p>
               </list-item>
            </list>
         </sec>
         <sec id="s3.2" sec-type="Molekularna klasifikacija celičnih linij raka dojk">
            <label>3.2</label>
            <title>Molekularna klasifikacija celičnih linij raka dojk</title>
            <p>Profiliranje genskega izražanja se je v zadnjem času pogosto uporabljalo za katalogiziranje CL RD. Dai in sod. so v svojem prispevku analizirali 84 CL na podlagi statusa ER, PR in HER2 ter jih razdelili ob upoštevanju klasifikacije LA, LB, HER2+ in TNRD (A in B podtipa) (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            <p>CL TNRD se v literaturi opredelijo kot bazalni tip A ali B. TNRD-A je bolj podoben podtipu (<italic>angl.</italic> luminal-like) in tip TNRD-B (<italic>angl.</italic> basal-like). Zaradi podobnosti med tipoma prihaja tudi do zmede v sami klasifikaciji. Primer tega je CL MDAMB468, ki je ponekod klasificirana kot bazalni tip A, v drugih prispevkih pa kot šibko luminalna vrsta. CL Hs578T in MDAMB231 sta ponekod opisani kot bazalni tip B in v drugih kot nizko klavdinski<italic> </italic>ali celo mezenhimskim podobne. Prikaz intrinzičnih podtipov raka in CL je na <xref ref-type="fig" rid="fig1">Sliki 1</xref> in v <xref ref-type="table" rid="table2">Tabeli 2</xref>. V <table-wrap position="float" id="table3">
                  <label>Tabela 3:</label>
                  <caption>
                     <p> Seznam celičnih linij raka dojk.</p>
                  </caption>
                  <table>
                     <colgroup>
                        <col/>
                        <col/>
                        <col/>
                        <col/>
                        <col/>
                        <col/>
                        <col/>
                        <col/>
                        <col/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th>CEL. LINIJE</th>
                           <th>ER</th>
                           <th>PR</th>
                           <th>HER2</th>
                           <th>BRCA1</th>
                           <th>PODT</th>
                           <th>SER</th>
                           <th>MEDIJ</th>
                           <th>TUM</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td>BT483</td>
                           <td>+</td>
                           <td>+/-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>LA</td>
                           <td>BT</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>CAMA1</td>
                           <td>+</td>
                           <td>+/-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>LA</td>
                           <td>NA</td>
                           <td>DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>EFM19</td>
                           <td>+</td>
                           <td>+</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>LA</td>
                           <td>EFM</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>HCC1428</td>
                           <td>+</td>
                           <td>+</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>LA</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>HCC712</td>
                           <td>+</td>
                           <td>+/-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>LA</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>IBEP2</td>
                           <td>+</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>LA</td>
                           <td>NA</td>
                           <td>DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>KPL1</td>
                           <td>+</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>LA</td>
                           <td>NA</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>LY2</td>
                           <td>+</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>LA</td>
                           <td>NA</td>
                           <td>DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MCF7</td>
                           <td>+</td>
                           <td>+</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>LA</td>
                           <td>MCF</td>
                           <td>RPMI, DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MDAMB134</td>
                           <td>+</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>LA</td>
                           <td>MDA</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MDAMB134VI</td>
                           <td>+</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>LA</td>
                           <td>MDA</td>
                           <td>DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MDAMB175</td>
                           <td>+</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>LA</td>
                           <td>MDA</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MDAMB175VII</td>
                           <td>+</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>LA</td>
                           <td>MDA</td>
                           <td>DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MDAMB415</td>
                           <td>+</td>
                           <td>+/-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>LA</td>
                           <td>MDA</td>
                           <td>DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>T47D</td>
                           <td>+</td>
                           <td>+</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>LA</td>
                           <td>NA</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>ZR751</td>
                           <td>+</td>
                           <td>+/-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>LA</td>
                           <td>ZR75</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>ZR75B</td>
                           <td>+</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>LA</td>
                           <td>ZR75</td>
                           <td>RPMI</td>
                           <td>NA</td>
                        </tr>
                        <tr>
                           <td>BSMZ</td>
                           <td>+</td>
                           <td>+</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>LB</td>
                           <td>NA</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>BT474</td>
                           <td>+</td>
                           <td>+</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>LB</td>
                           <td>BT</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>EFM192A</td>
                           <td>+</td>
                           <td>+</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>LB</td>
                           <td>EFM</td>
                           <td>RPMI</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>BEP1</td>
                           <td>-</td>
                           <td>+</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>LB</td>
                           <td>IBEP</td>
                           <td>DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>IBEP3</td>
                           <td>-</td>
                           <td>+</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>LB</td>
                           <td>IBEP</td>
                           <td>DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MDAMB330</td>
                           <td>+</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>LB</td>
                           <td>MDA</td>
                           <td>RPMI</td>
                           <td>ILC</td>
                        </tr>
                        <tr>
                           <td>MDAMB361</td>
                           <td>+</td>
                           <td>+/-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>LB</td>
                           <td>MDA</td>
                           <td>RPMI, DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>UACC812</td>
                           <td>+</td>
                           <td>+/-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>LB</td>
                           <td>UACC</td>
                           <td>RPMI, DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>ZR7527</td>
                           <td>+</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>LB</td>
                           <td>ZR75</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>ZR7530</td>
                           <td>+</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>LB</td>
                           <td>ZR75</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>21MT1</td>
                           <td>-</td>
                           <td>+/-</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>H</td>
                           <td>21</td>
                           <td>α-MEM/DFC1</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>21MT2</td>
                           <td>-</td>
                           <td>+/-</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>H</td>
                           <td>21</td>
                           <td>α-MEM/DFC1</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>21NT</td>
                           <td>-</td>
                           <td>+/-</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>H</td>
                           <td>21</td>
                           <td>α-MEM/DFC1</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>21PT</td>
                           <td>-</td>
                           <td>+/-</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>H</td>
                           <td>21</td>
                           <td>α-MEM/DFC1</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>AU565</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>NA</td>
                           <td>RPMI</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>HCC1008</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>H</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>HCC1569</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>MC</td>
                        </tr>
                        <tr>
                           <td>HCC1954</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC202</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC2218</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>H</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HH315</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>H</td>
                           <td>HH</td>
                           <td>RPMI</td>
                           <td>C</td>
                        </tr>
                        <tr>
                           <td>HH375</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>ND</td>
                           <td>H</td>
                           <td>HH</td>
                           <td>RPMI</td>
                           <td>C</td>
                        </tr>
                        <tr>
                           <td>KPL-4</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>KPL</td>
                           <td>DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MDAMB453</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>MDA</td>
                           <td>RPMI, DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>OCUB-F</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>NA</td>
                           <td>RPMI</td>
                           <td>NA</td>
                        </tr>
                        <tr>
                           <td>SKBR3</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>SKBR</td>
                           <td>RPMI, McCoys</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>SKBR5</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>SKBR</td>
                           <td>RPMI</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>SUM190PT</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>SUM</td>
                           <td>Ham's F12</td>
                           <td>Inf</td>
                        </tr>
                        <tr>
                           <td>SUM225CWN</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>SUM</td>
                           <td>Ham's F12</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>UACC893</td>
                           <td>-</td>
                           <td>-</td>
                           <td>+</td>
                           <td>WT</td>
                           <td>H</td>
                           <td>UACC</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>BT20</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>BT</td>
                           <td>RPMI, DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>CAL148</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>CAL</td>
                           <td>DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>DU4475</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>NA</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>EMG3</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>TNRD-A</td>
                           <td>NA</td>
                           <td>DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>HCC1143</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>TNRD-A</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC1187</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>TNRD-A</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC1599</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>TNRD-A</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC1806</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>TNRD-A</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>SqC</td>
                        </tr>
                        <tr>
                           <td>HCC1937</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>MU</td>
                           <td>TNRD-A</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC2157</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>TNRD-A</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC3153</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>MU</td>
                           <td>TNRD-A</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC70</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HMT3522</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>HMT</td>
                           <td>DMEM, F12</td>
                           <td>B</td>
                        </tr>
                        <tr>
                           <td>KPL-3C</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>TNRD-A</td>
                           <td>KPL</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MA11</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>TNRD-A</td>
                           <td>NA</td>
                           <td>DMEM</td>
                           <td>ILC</td>
                        </tr>
                        <tr>
                           <td>MDAMB435</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>MDA</td>
                           <td>DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>MDAMB436</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>MU</td>
                           <td>TNRD-A</td>
                           <td>MDA</td>
                           <td>RPMI, L15</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>MDAMB468</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>MDA</td>
                           <td>RPMI, L15</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>MFM223</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>NA</td>
                           <td>MEM</td>
                           <td>C</td>
                        </tr>
                        <tr>
                           <td>SUM185PE</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>SUM</td>
                           <td>Ham's F12</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>SUM229PE</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-A</td>
                           <td>SUM</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>BT549</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>
                              <p>TNRD-B</p>
                              <p>TNRD-B</p>
                           </td>
                           <td>BT</td>
                           <td>RPMI</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>CAL120</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>
                              <p>TNRD-B</p>
                              <p>TNRD-B</p>
                           </td>
                           <td>CAL</td>
                           <td>DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>CAL51</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>
                              <p>TNRD-B</p>
                              <p>TNRD-B</p>
                           </td>
                           <td>CAL</td>
                           <td>DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>CAL851</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>
                              <p>TNRD-B</p>
                              <p>TNRD-B</p>
                           </td>
                           <td>CAL</td>
                           <td>DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>HCC1395</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>
                              <p>TNRD-B</p>
                              <p>TNRD-B</p>
                           </td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC1739</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>
                              <p>TNRD-B</p>
                              <p>TNRD-B</p>
                           </td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HCC38</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>ND</td>
                           <td>TNRD-B</td>
                           <td>HCC</td>
                           <td>RPMI</td>
                           <td>DC</td>
                        </tr>
                        <tr>
                           <td>HDQ-P1</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>MU</td>
                           <td>TNRD-B</td>
                           <td>NA</td>
                           <td>DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>Hs578T</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-B</td>
                           <td>NA</td>
                           <td>RPMI, DMEM</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>MDAMB157</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-B</td>
                           <td>MDA</td>
                           <td>RPMI, DMEM</td>
                           <td>MC</td>
                        </tr>
                        <tr>
                           <td>MDAMB231</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-B</td>
                           <td>MDA</td>
                           <td>RPMI, DMEM</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>SKBR7</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-B</td>
                           <td>SKBR</td>
                           <td>RPMI</td>
                           <td>AC</td>
                        </tr>
                        <tr>
                           <td>SUM102PT</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-B</td>
                           <td>SUM</td>
                           <td>Ham's F12</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>SUM1315M02</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>MU</td>
                           <td>TNRD-B</td>
                           <td>SUM</td>
                           <td>Ham's F12</td>
                           <td>IDC</td>
                        </tr>
                        <tr>
                           <td>SUM149PT</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>MU</td>
                           <td>TNRD-B</td>
                           <td>SUM</td>
                           <td>Ham's F12</td>
                           <td>InfDC</td>
                        </tr>
                        <tr>
                           <td>SUM159PT</td>
                           <td>-</td>
                           <td>-</td>
                           <td>-</td>
                           <td>WT</td>
                           <td>TNRD-B</td>
                           <td>SUM</td>
                           <td>Ham's F12</td>
                           <td>AnC</td>
                        </tr>
                     </tbody>
                  </table>
                  <table-wrap-foot>
                     <p>Legenda: PODT – podtip RD, SER – serija CL, MEDIJ – uporabljen rastni medij, TUM – vrsta izvornega tumorja, WT – divji tip (<italic>angl.</italic> wild type), ND – nedoločeno, LA – luminalni tip A, LB – luminalni tip B, H - HER2 pozitiven, TNRD-A – trojno negativen A, TNRD-B – trojno negativen B, AC – adenokarcinom, AnC – anaplastični karcinom, B – benigni tumor, C – karcinom, CS – karcinosarkom, DC – duktalni karcinom, IDC – invazivni duktalni karcinom, ILC – invazivni lobularni karcinom, InfC – vnetni karcinom, InfDC – vnetni duktalni karcinom, MC – medularni karcinom, SqC – skvamozni karcinom, NA – ni podatkov. Tabela 3 je povzeta po Dai in sod. (<xref ref-type="bibr" rid="b5">5</xref>), uporabljeno z licenco CC BY-NC 4.0.</p>
                  </table-wrap-foot>
               </table-wrap>
               <xref ref-type="table" rid="table3">Tabeli 3</xref> je naveden seznam bolj znanih CL.</p>
            <fig position="anchor" id="fig1">
               <label>Slika 1:</label>
               <caption>
                  <p> Primerjava med trenutnimi načini kategorizacije RD in njegovimi CL.</p>
               </caption>
               <p>
                  <graphic xlink:href="2842-web-resources/image/zdravvestn-2842-sl-01.png"/>
               </p>
               <p>Glede na status hormonskih receptorjev in HER2 se RD deli na luminalni tip A in B, HER2+ ter TNRD, ki ga lahko delimo na bazalni, nizko klavdinski, metaplastični in z interferonom bogat RD. <xref ref-type="fig" rid="fig1">Slika 1</xref> je povzeta po Dai in sod. (<xref ref-type="bibr" rid="b5">5</xref>), uporabljeno z licenco CC BY-NC 4.0.</p>
            </fig>
            <table-wrap position="anchor" id="table2">
               <label>Tabela 2:</label>
               <caption>
                  <p> Molekularne in morfološke značilnosti CL RD. </p>
                  <p/>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>PODTIP CL</th>
                        <th/>
                        <th colspan="2">mRNA</th>
                        <th>miRNA</th>
                        <th>PROTEIN</th>
                        <th>MORFOLOGIJA</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>Luminal</td>
                        <td/>
                        <td colspan="2">ER, GATA3, KRT19/KRT8/KRT18, XBP1, PBX1, ZNF278, SPDEF, CRABP2, MUC1, FOXA1, MYB, RET, EGR3, TFF1, HER3, TOB1, TFF3</td>
                        <td>
                           <p>hsa-miR-501–5p,</p>
                           <p>hsa-miR-202</p>
                           <p>hsa-miR-760</p>
                           <p>hsa-miR-626</p>
                        </td>
                        <td>ER, GATA3, KRT19</td>
                        <td>Bolj diferenciran; več medceličnih tesnih stikov.</td>
                     </tr>
                     <tr>
                        <td>HER2+</td>
                        <td/>
                        <td colspan="2">HER2, GRB7, PERLD1, STARD3, C17ORF37 hsa-let-7b</td>
                        <td>
                           <p>hsa-miR-640</p>
                           <p>hsa-miR-200c</p>
                           <p>hsa-miR-378</p>
                           <p>hsa-miR-141</p>
                           <p>hsa-miR-196a</p>
                           <p>hsa-miR-29c</p>
                           <p>hsa-miR-18a*</p>
                        </td>
                        <td>HER2</td>
                        <td>Razpad medceličnih tesnih stikov.</td>
                     </tr>
                     <tr>
                        <td>TNRD</td>
                        <td>
                           <p>Trojno negativni A</p>
                           <p>(Bazalni tip A)</p>
                        </td>
                        <td rowspan="2">
                           <p>EGFR</p>
                           <p>CAV1/2</p>
                           <p>MSN</p>
                           <p>ETS1</p>
                        </td>
                        <td>KRT4/5/6A/6B/13/14/15/16/17, ITGA6, ITGB4/6, LAMB3, LAMC2, TRIM29, S100A2, SLPI, LYN, ANXA8, COL17A1, BNC1, MET, CD133, GABRK, VTCN1, BST2, FABP7, CD10/14/58/59.</td>
                        <td>
                           <p>hsa-miR-492</p>
                           <p>hsa-miR-26b</p>
                           <p>hsa-miR-617</p>
                           <p>hsa-miR-155</p>
                        </td>
                        <td>
                           <p>EGFR</p>
                           <p>CAV1/2</p>
                           <p>MSN</p>
                           <p>ETS1</p>
                           <p>KRT5/6</p>
                           <p>CD10</p>
                           <p>MET</p>
                        </td>
                        <td>
                           <italic>Angl.</italic> core basal-like.</td>
                     </tr>
                     <tr>
                        <td/>
                        <td>
                           <p>Trojno negativniB</p>
                           <p>(Bazalni tip B)</p>
                        </td>
                        <td>
                           <p>VIM, SPARC, FN1, FBN1, HSA2, PRG1,</p>
                           <p>COL3A1, COL6A1/2/3, COL8A1, MMP2/14,</p>
                           <p>TIMP1, CTSC, PLAU, PLAUR, AXL, PLAT,</p>
                           <p>CD24(-), CD44, TGFBR2, SERPINE1/2, TGFB1</p>
                        </td>
                        <td>
                           <p>hsa-miR-22</p>
                           <p>hsa-miR-532–3p</p>
                           <p>hsa-miR-125b</p>
                           <p>hsa-miR-501–5p</p>
                           <p>hsa-miR-155*</p>
                        </td>
                        <td>CD44</td>
                        <td>Najslabše diferenciran in največ podobnosti z matičnimi celicami; bolj mezenhimskim podoben izgled in zelo invaziven.</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Legenda: CL – celične linije, TNRD – trojno negativni RD. Tabela 2 je povzeta po Dai in sod. (5), uporabljeno z licenco CC BY-NC 4.0.</p>
               </table-wrap-foot>
            </table-wrap>
         </sec>
         <sec id="s3.3" sec-type="Celične linije luminalnega raka dojk">
            <label>3.3</label>
            <title>Celične linije luminalnega raka dojk</title>
            <p>Za luminalni tip RD je značilna izraženost ER+ in/ali PR+. V literaturi je opisana sistematska raziskava profiliranja izraženosti mikro RNA (miRNA), ki je pokazala specifično povečano izraženost hsa-miR-501–5p, hsa-miR-202, hsa-miR-760 in hsa-miR-626 v luminalnih celičnih linijah (LCL), ki so edinstvene za LCL brez ERBB2 izraženosti (HER2-) in zato v pomoč pri specifikaciji posameznega podtipa CL. Prav tako so te miRNA povezane z genskimi mutacijami E-kadherina (supresivni učinek na rast) oz. z njegovo izgubo. Zato so LCL bolj diferencirane in so manj nagnjene k migraciji zaradi tesnih celičnih stikov (<xref ref-type="bibr" rid="b25">25</xref>).</p>
            <p>Čeprav se v literaturi pogosto LCL ne deli na A in B podtipe glede na njihov status HER2, je takšen način kategorizacije pomemben za enotno nomenklaturo, lažje modeliranje in pri načrtovanju odgovora na poskuse zdravljenja. LCL tipa B so pogosto bolj invazivne in bolj agresivne kot LCL tipa A. V literaturi je opisano, da povečana izraženost HER2 pogosto korelira z zmanjšano izraženostjo ER oz. z zniževanjem ravni izražanja ER (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            <p>Bolnice, ki imajo hormonsko odziven RD, prejmejo hormonsko terapijo (npr. tamoksifen, letrozol, anastrozol, eksemestan), določene posameznice pa še kemoterapijo (npr. adriamicin/ciklofosfamid; adriamicin/ciklofosfamid/paklitaksel; docetaksel/ciklofosfamid) (<xref ref-type="bibr" rid="b26">26</xref>).</p>
         </sec>
         <sec id="s3.4" sec-type="Celične linije HER2 + raka dojk">
            <label>3.4</label>
            <title>Celične linije HER2 + raka dojk</title>
            <p>HER2+ CL (ER- in HER2+) imajo pogosto značilne spremembe v kromosomski regiji 17q12, ki vključuje gene HER2, GRB7 (na rastni faktor vezani protein 7), PERLD1, STARD3 in C17ORF37 (<xref ref-type="bibr" rid="b27">27</xref>). Povečano izražanje teh genov igra pomembno vlogo v onkogenezi RD in primernem načinu zdravljenja.</p>
            <p>Prav tako je povečana izraženost miRNA hsa-let-7b, hsa-miR-640, hsa-miR-200c, hsa-miR-378, hsa-miR-141, hsa-miR-196a, hsa-miR-29c in hsa-miR-18a, ki so značilne za CL s povečano izraženostjo ERBB2 (<xref ref-type="bibr" rid="b25">25</xref>). V literaturi je omenjen pomen povečane koekspresije HER2 genov <italic>STARD3</italic>, <italic>GRB7</italic>, <italic>PSMD3</italic> in <italic>PERLD1</italic>, ki omogočajo rast rakavih celic. Utišanje omenjenih genov namreč omogoča aditivno znižanje celične viabilnosti kot tudi vodi v inducirano apoptozo. Simultano ciljano utišanje tarčnih genov lahko poveča učinkovitost t. i. anti-HER2 terapij ter nasprotuje odpornosti na transtuzumab (<xref ref-type="bibr" rid="b28">28</xref>). HER2+ CL so zaradi svojih lastnosti vmesna postaja med LCL in BCL. Izkazujejo tako lastnosti luminalnih kot tudi bazalnih CL. Na podlagi izraženosti luminalnih in bazalnih označevalcev, razen ER in HER2, jih lahko delimo še na luminalne-ERBB2+ in ER-negative-ERBB2+ (<xref ref-type="bibr" rid="b25">25</xref>). V skladu z njihovimi molekularnimi lastnostmi so celice tega podtipa bolj agresivne v primerjavi z LCL, saj je povečana izraženost HER2 povezana z razgradnjo celičnih stikov (<xref ref-type="bibr" rid="b25">25</xref>). Povečana izraženost proteinov estrogenski receptor 1 (ESR1), mitogen-aktivirana proteinska kinaza 1 (MAPK1/3), kinaza z mitogenom aktivirane protein kinaze (MEK ali MAPKK), tirozin kinaza 2 (TYK2), sintaza maščobnih kislin (FASN) in na rastni faktor vezani protein 7 (GRB7) je povezana z večjo občutljivostjo na transtuzumab (<xref ref-type="bibr" rid="b29">29</xref>). Povečana izraženost na rastni faktor vezanega proteina 2 (GRB2), retinoblastomskega proteina (RB1) in filamina alfa (FLNA) pa nakazuje večjo odpornost na transtuzumab. Prav tako lahko na odpornost trastuzumab nakazujejo mitogen-aktivirana proteinska kinaza (MAPK), tarča rapamicina pri sesalcih (mTOR) in <italic>Toll-like</italic> receptorske signalne poti kot tudi N-glikan biosinteza ter inozitol-fosfat signalizacija (<xref ref-type="bibr" rid="b29">29</xref>).</p>
            <p>Standardna farmakološka terapija za bolnice s HER2 pozitivnim RD je tarčna v kombinaciji s kemoterapijo (npr. paklitaksel/trastuzumab; adriamicin/ciklofosfamid/paklitaksel/trastuzumab +/- pertuzumab; docetaksel/karboplatin/trastuzumab ± pertuzumab) in, ob pozitivnih hormonskih receptorjih, še hormonska terapija (tamoksifen, letrozol, anastrozol ali eksemestan) (<xref ref-type="bibr" rid="b26">26</xref>).</p>
         </sec>
         <sec id="s3.5" sec-type="Celične linije TNRD">
            <label>3.5</label>
            <title>Celične linije TNRD</title>
            <p>Izmed podtipov CL je TNRD najbolj heterogen. TNRD CL imajo zelo nizko izraženost ali pa so brez vseh treh označevalcev (ER-, PR-, HER2-). TNRD lahko delimo na dva bazalna podtipa: TNRD-A in TNRD-B.</p>
            <p>TNRD-A linije se pogosto poimenujejo bazalnim podobne linije zaradi prisotnosti:</p>
            <p>1.citokeratinov (KRT4/5/6A/6B/13/14/ 15/16/17),</p>
            <list>
               <list-item>
                  <label>2.</label>
                  <p>integrinov (ITGA6, ITGB4/6) in</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>LAMB3, LAMC2, TRIM29, S100A2, SLPI, ANXA8, COL17A1, BNC1, CD10/14/58/59, MET, LYN, CD133, GABRK, VTCN1, BST2, FABP7 (<xref ref-type="bibr" rid="b25">25</xref>).</p>
               </list-item>
            </list>
            <p>Za TNRD-B CL je značilna povečana izraženost genov, ki so povezani z agresivnimi in invazivnimi lastnosti: vimentin (VIM), moezin (MSN), plazminogen aktivator tkivne vrste (PLAT), transformirajoči rastni faktor beta-1 (TGFB1), transformirajoči rastni faktor beta-2 prekurzor (TGFBR2), tirozin-protein kinazni receptor UFO (AXL), kolageni (COL3A1, COL6A1/2/3, COL8A1), matriks metalopeptidaza (MMP2/14) metalopeptidaza inhibitor (TIMP1) ipd. (<xref ref-type="bibr" rid="b5">5</xref>); ter lastnost podobnosti matičnih rakastih celic, kot so CD44(+) in CD24(- ) (<xref ref-type="bibr" rid="b29">29</xref>,<xref ref-type="bibr" rid="b30">30</xref>).</p>
            <p>Kolageni (COL3A1, COL6A1/2/3, COL8A1), proteaze (MMP2/14, TIMP1, CTSC, PLAU, PLAUR, SERPINE1/2, PLAT, uPA, PAi) in interakcije med proteini za stabilizacijo citoskeleta (VIM, MSN) so pomembni pri remodeliranju zunajceličnega matriksa, ki je odgovoren za celično migracijo. Signalni faktorji (TGFB1, TGFBR2, AXL) pa so ključnega pomena za nastanek agresivne morfologije. Ob tem se uporabljajo tudi določeni proteini (EGFR, CAV1/2, MSN, ETS1) za karakterizacijo TNRD CL (<xref ref-type="bibr" rid="b31">31</xref>,<xref ref-type="bibr" rid="b32">32</xref>).</p>
            <p>Za opredelitev TNRD-A in B CL se uporabljajo specifične miRNA. Pri tipu A je prisotna predvsem povečana izraženost hsa-miR-492, hsa-miR-26b, hsa-miR-617 in hsa-miT-155. Pri tipu B pa je povečana izraženost hsa-miR-22, hsa-532–3p, hsa-miR-125b, hsa-miR-501–5p, hsa-miR-155. Zanimivo je, da hsa-miR-155 oz. miR-155–5p (TNRD-A) in hsa-miR-155* oz. miR-155–3p (TNRD-B) izvirata iz enakega prekurzorja, vendar izkazujeta nasprotujoči vzorec izražanja pri teh tipih TNRD (<xref ref-type="bibr" rid="b25">25</xref>).</p>
            <p>Onkogena vloga hsa-miR-155 je dobro opisana pri levkemijah. Prav tako naj bi igrala pomembno vlogo v kardiovaskularnem sistemu (okvara vodi do hipertenzije) in imunskem odgovoru. Nekateri od predlaganih načinov delovanja so v sklopu apoptoze, diferenciacije, angiogeneze, proliferacije in epitelne mezenhimske tranzicije.</p>
            <p>Fenotipsko so TNRD-A celice bolj diferenciran podtip od TRND-B in imajo lahko ali luminalnemu podobne ali bazalnemu podobne morfološke značilnosti. TNRD-B celice imajo bolj mezenhimsko podoben izgled in imajo večjo tendenco k invaziji. Zato so TNRD-A CL večinoma podobne osrednjemu bazalnemu tumorskemu podtipu. TNRD-B celice se lahko uporabijo za modeliranje nizkoklavdinskega ali metaplastičnega RD (<xref ref-type="bibr" rid="b33">33</xref>).</p>
            <p>BRCA1 kodira protein, ki oblikuje Rap80/Abraxas/BRCA1/Brcc36 kompleks kot odgovor na poškodbe DNA. Mutacije tega gena so povezane z dedno obliko RD, ki je podoben sporadičnemu jedrnemu bazalnemu tumorju. TNRD-A CL so karakterizirane z BRCA1 mutacijskim vzorcem. Večina trenutno dostopnih CL RD (HCC1937, MDAMB436, SUM149PT, HCC3153) spadajo k temu podtipu (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b34">34</xref>).</p>
            <p>Standardni farmakološki način zdravljenja bolnic s TNRD je uporaba kemoterapije (adriamicin/ciklofosfamid; adriamicin/ciklofosfamid/paklitaksel; docetaksel/ciklofosfamid) (<xref ref-type="bibr" rid="b26">26</xref>).</p>
         </sec>
         <sec id="s3.6" sec-type="Gojenje celičnih linij raka dojk">
            <label>3.6</label>
            <title>Gojenje celičnih linij raka dojk</title>
            <sec id="s3.6.1" sec-type="Izoliranje, gojenje in karakterizacija">
               <label>3.6.1</label>
               <title>Izoliranje, gojenje in karakterizacija</title>
               <p>Po odstranitvi tumorja se tkivo shrani v rastni medij za gojenje celičnih kultur (npr. <italic>Advanced</italic> DMEM/F12). Če se tkivo prenaša, mora celotni postopek ves čas potekati na hladnem (na ledu) in čim hitreje, da se zmanjša čas hladne ishemije. Nato se prične z izoliranjem celic. Celoten postopek poteka v sterilnem okolju v zaščitni mikrobiološki komori. Koščki tkiva se prenesejo v petrijevke in se 2-krat sperejo s PBS z dodatkom antibiotikov (npr. penicilin in streptomicin). Tkivo se ponovno prelije s PBS, nato se odstranijo odmrli kosi tkiva. V posebni petrijevki se pripravi mešanica učinkovin za encimsko razgradnjo (npr. tripsin/EDTA) in vanj odložijo koščki tumorja. Po mehanski in encimski obdelavi sledi selekcija primernih celic za naslednji korak inkubacije/propagacije. Natančen protokol izoliranja je podrobneje opisan v prispevku Gradišnik in sod (<xref ref-type="bibr" rid="b35">35</xref>).</p>
               <p>Nekaj dni po izoliranju se v fazi propagacije celice prično pritrjati na podlago. Če je večina celic še vedno nepritrjenih, se celotna suspenzija celic iz posameznih posodic centrifugira na 1400 vrt/min, 5 minut, sedimentu celic pa doda svež medij s serumom (npr. 5-odstotni <italic>angl.</italic> fetal bovine serum) ter jih vrne v posodice. Na ta način se vsak drugi ali tretji dan menjava medij, dokler večina celic ni adherentnih. Po tednu do dveh (odvisno od vrste celic) od izoliranja se različni tipi celic pritrdijo na podlago, s čimer se vzgoji primarna kultura, ki se zamrzne. Del primarne celične kulture se goji dalje za pridobitev čiste CL. Iz celične kulture je potrebno odstraniti vse ostale celične tipe (npr. fibroblaste). Za nadaljnje delo se lahko uporabi več pristopov, dokler ne prevlada morfološko epitelni tip celic.</p>
               <p>Določanje lastnosti CL poteka na več različnih načinov in z različnimi metodami ter se imenuje proces karakterizacije. Najpogosteje uporabljene metode so: morfološka analiza, kariotipizacija, STR profiliranje, genska ekspresija, imunohistokemija in/ali imunocitokemija ter funkcionalni testi (<xref ref-type="bibr" rid="b36">36</xref>).</p>
            </sec>
            <sec id="s3.6.2" sec-type="Mutacije">
               <label>3.6.2</label>
               <title>Mutacije</title>
               <p>Pojav DNA alteracij je večji pri CL RD kot pri tumorjih. Povprečno so alteracije CL dvakrat pogostejše kot pri tumorjih (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b37">37</xref>). Vzrok temu je lahko dejstvo, da CL večinoma izvirajo iz invazivnih tumorjev z visokih gradusom. V takšnih celicah hitreje pride do genomskih sprememb v procesu <italic>in vitro</italic>
                  <italic> </italic>kultivacije. Zato imajo CL RD spremembe v zapisu DNA, ki niso prisotne v prvotnem tkivu ter so zgolj posledica kultivacije. Takšne <italic>de novo</italic> mutacije lahko privedejo do fenotipskih sprememb. Primer je MCF-7 CL, pri kateri je prisotna variabilna občutljivost na tamoksifen (<xref ref-type="bibr" rid="b38">38</xref>). Kljub temu je na podlagi podatkov primerjalne genomske hibridizacije (CGH) prisotno mnenje, da so CL, kar se tiče glavnih oz. pomembnejših DNA sprememb, primerljive s prvotnim tkivom (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b37">37</xref>-<xref ref-type="bibr" rid="b39">39</xref>).</p>
               <p>Obstaja pa še druga vrsta karcinogenih dejavnikov vpliva na vzorce izražanja cele vrste genov. Ti dejavniki spremenijo izražanje nekaterih kritičnih genov (ter nastanek in delovanje njihovih produktov) brez neposrednega vpliva na DNA-zaporedje. Ta način delovanja imenujemo epigenetsko delovanje. Tako pri epigenetskih spremembah kot tudi pri genetskih spremembah je potrebno, da se novi vzorec vtisne v na novo zasnovan celični spomin in se prenese v naslednje generacije celic (<xref ref-type="bibr" rid="b40">40</xref>). Ti mehanizmi so prav tako podobni med CL RD in tumorji. V literaturi je opisano, da so bili metilacijski vzorci CpG-otokov primerljivi med CL in tumorjem. Geni, pri katerih je bil prisoten metilacijski vzorec na promotorski regiji, so bili: ER, PR, protein hipermetiliran pri raku 1 (HIC1), protein adenomatzne polipoze kolona (APC), rak dojk 1 (BRCA1) ipd. Ob tem pa so poročali tudi o neskladnostih na drugih genih (<xref ref-type="bibr" rid="b41">41</xref>).</p>
               <p>Iz literature je razvidno, da so na molekularni ravni diskriminativni označevalci in iz tega sledeče fenotipske značilnosti prisotne v CL pogosto tudi značilne za tumorsko tkivo. Npr. geni, ki korelirajo z ER+ ali ER- fenotipom pri CL RD, so povezani s pozitivno ali negativno korelacijo ER izraženosti v tumorskem tkivu (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            </sec>
            <sec id="s3.6.3" sec-type="Celično okolje">
               <label>3.6.3</label>
               <title>Celično okolje</title>
               <p>Na celično okolje vpliva več dejavnikov; rastni medij, parametri gojenja (temperatura, atmosfera itd.), rast v 2D ali 3D kulturah ali kot ksenograft in dodani rastni dejavniki.</p>
               <p>Kompleksne medcelične komunikacije se v <italic>in vivo</italic>
                  <italic> </italic>okolju, kadar so CL vzgojene v plastičnih posodah in dvodimenzionalnih razsežnostih, izgubijo. CL so občutljive na razmere v kulturi. To velja predvsem za dodatek rastnih faktorjev, ki lahko spremenijo celični fenotip in vodijo v neprimerno aktiviranje signalnih poti ali diferenciacijo. Gojenje v neprimernem okolju lahko drastično vpliva na celično morfologijo, interakcije med celicami in celico ter matriksom, celično polarnost in diferenciacijo kot tudi na spremembo signalnih kaskad genske izraženosti (<xref ref-type="bibr" rid="b42">42</xref>).</p>
               <p>Identifikacija najbolj primernih pogojev za celično rast in gojenje specifičnega fenotipa je izrednega pomena. Kot model imajo 2D kulture številne pomanjkljivosti, še posebej v primerjavi s 3D sistemi (npr. organoidi ali 3D tiskani modeli). 2D in 3D kulture se prav tako uporabljajo za proučevanje delovanja zdravilnih učinkovin. Ni presenetljivo, da so tumorske celice v 3D kulturah bolj odporne oz. manj občutljive na zdravilne učinkovine v primerjavi s celicami v 2D kulturah (<xref ref-type="bibr" rid="b42">42</xref>). Razlog temu je lahko zmanjšan dostop do sestavin učinkovine v mediju, patofiziološke razlike, ki nastanejo zaradi hipoksije v 3D kulturah ali sprememb v celičnem ciklu. Prav tako je opisan pomen nestabilnih razmer, ki se pojavijo v okolju <italic>in vitro</italic> (npr. t. i. <italic>de novo</italic> mutacije). Ob tem so pomembne metode kultiviranja, ki pomembno vplivajo na celično metabolno aktivnost, celično proliferacijo in v končni fazi tudi na občutljivost celic na zdravilno učinkovino. Dokazano je bilo, da med 2D, 3D in sferoidnimi modeli CL, samo 3D celične kulture izkazujejo primerljivo gostoto celic kot naravno tkivo in tudi primerljiv odziv na zdravila kot solidni tumor (<xref ref-type="bibr" rid="b42">42</xref>,<xref ref-type="bibr" rid="b43">43</xref>).</p>
               <p>Interakcije med celicami in zunajceličnim matriksom igrajo pomembno vlogo v mehanizmih odpornosti rakastih celic na zdravila. Celice, ki se gojijo v 3D svilenem ogrodnem sistemu, ki ima podobno prepredenost, orientacijo in velikost vlaken kot zunajcelični matriks tumorskega tkiva, so bolj odporne na paklitaksel (<xref ref-type="bibr" rid="b44">44</xref>). Spremembe v arhitekturi umetnega zunajceličnega matriksa so bile povezane z napredovanjem raka. V tem kontekstu bi lahko 3D sistemi omogočili, da se v kliničnem okolju izognemo neprimernemu odmerjanju zdravilne učinkovine v primerih odpornosti (<xref ref-type="bibr" rid="b42">42</xref>).</p>
            </sec>
         </sec>
         <sec id="s3.7" sec-type="Omejitve in dileme uporabe in vitro CL">
            <label>3.7</label>
            <title>Omejitve in dileme uporabe in vitro CL</title>
            <p>Kljub pomembni vlogi, ki jo igrajo CL RD v procesu raziskovanja in odkrivanja mehanizmov tumorske iniciacije in evolucije, imajo tudi svoje pomanjkljivosti.</p>
            <p>Potrebno je poudariti dilemo o prenosljivosti dognanj na CL v klinično okolje (<xref ref-type="bibr" rid="b45">45</xref>). Čeprav so tkiva v večinskem deležu identična glede na glavno določitev receptorskega in statusa HER2, je v zadnjem času vedno več znanega o naknadnih drastičnih genetskih in epigenetskih spremembah v sklopu vzgajanja linije v laboratorijskem okolju. Zato ostaja odprto vprašanje o primerljivosti molekularnih značilnosti, heterogenosti RD in CL (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b45">45</xref>). Klonalna populacija ene CL ne more dodobra prikazati raznolikosti procesov na znotraj tumorski ravni. Karcinogeneza je večstopenjski proces, ki vključuje mnogo kliničnih in patoloških stopenj. Med te sodijo tipična hiperproliferacija, lokalna invazija, tvorba invazivnega karcinoma in v končni fazi razsoj bolezni. Ta proces spremljajo postopne pridobitve različnih vrst genetskih in epigenetskih mutacij celic, ki jim sledijo klonalna selekcija in ekspanzija.</p>
            <p>V fazi kultiviranja CL lahko pride do eliminacije določenega tipa celic, ki so sprva prisotne v tkivu, vendar se zaradi dejavnikov okolja ne morejo razviti. Vzroki so lahko v porušenem mikrookolju ali pomanjkanju posebnih dejavnikov. Zato lahko pride do njihovega propada in s tem do spremembe heterogenosti tumorja. Primer tega so celice, ki na plastični površini ali sploh ne rastejo oz. brez dodatka specifičnih dejavnikov iz tumorskega mikrookolja ne morejo uspevati, zato odmrejo. Zato se poraja vprašanje, ali je potencialna CL, ki bi lahko služila kot model tumorja in ob tem ohranjala vso heterogenost, sploh mogoča.</p>
            <p>Uspeh v dolgoročni propagaciji je pomemben omejitveni dejavnik pri izdelavi kakovostne CL. Primer tega so CL TNRD. Ta podvrsta raka ima vsaj 4 podtipe: jedrno bazalen, nizko klavdinski, metaplastični in bogat z interferonom. Vsak od naštetih ima pomembne molekularne značilnosti in klinične implikacije. Na razpolago so zgolj linije TNRD-A in TNRD-B. TNRD-A je večinoma dobro reprezentativna za jedrno bazalni podtip, TNRD-B pa je uporaben za modeliranje nizko klavdinskega in/ali metaplastičnega podtipa. Prisotno pa je pomanjkanje za podtip bogat z interferonom. Prav tako je zelo malo CL (npr. MCF7, T-47D, MDAMB231), kljub celotnemu številu, ki so se uveljavile na trgu. Glede na tehnične težave pri ekstrakciji viabilnega tumorskega tkiva iz okoliške strome, je večina RD prvotno iz tkiva invazivnega karcinoma, kar nas vodi do razmisleka o reprezentativnosti prvotnega tkiva. Takšen primer je v literaturi opisan za CL MDAMB435, katerega prvotno tkivo je morebiti bilo v resnici okultni melanom (<xref ref-type="bibr" rid="b46">46</xref>).</p>
            <p>V literaturi so tudi opisani vplivi fibroblastov na morfološke spremembe CL. Opisan je bil vpliv fibroblastov na stimulacijo izraženosti luminalnih keratinov v bazalnih celicah in bazalnih keratinov v luminalnih celicah. Prav tako je bilo opisano, da celice, vzgojene v okolju z visoko/nizko EGFR aktivnostjo, pogosto postanejo ER+/-. To nakazuje na pomen vpliva okolja pri vzgoji CL (<xref ref-type="bibr" rid="b47">47</xref>). Dodaten pomislek pri uporabi CL RD je ponovljivost v različnih laboratorijih ali drugačnih pogojih. V teh primerih lahko CL razvijejo drugačne lastnosti. V literaturi so vidni primeri različne kategorizacije iste CL v edinstvene skupine na podlagi drugačnega molekularnega in morfološkega opisa.</p>
            <p>Pregled teh anomalij so opisali Dai in sod. (<xref ref-type="bibr" rid="b5">5</xref>). Primeri, ki so jih izpostavili, so pomembni za status HER2 in ER. Prikaz teh anomalij je v <xref ref-type="table" rid="table4">Tabeli 4</xref>.</p>
            <table-wrap position="anchor" id="table4">
               <label>Tabela 4:</label>
               <caption>
                  <p> Osem celičnih linij, ki jih literatura različno opredeljuje glede receptorskega statusa.</p>
                  <p/>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>Celične linije</th>
                        <th>ER</th>
                        <th>PR</th>
                        <th>HER2</th>
                        <th>Podtip</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>HCC1007</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>HCC1007</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                     <tr>
                        <td>HCC1007</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>HER2+</td>
                     </tr>
                     <tr>
                        <td>HCC1419</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                     <tr>
                        <td>HCC1419</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>HER2+</td>
                     </tr>
                     <tr>
                        <td>HCC1500</td>
                        <td>+</td>
                        <td>+</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>HCC1500</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>TNRD-B</td>
                     </tr>
                     <tr>
                        <td>HCC2185</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>TNRD-A</td>
                     </tr>
                     <tr>
                        <td>HCC2185</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>HER2+</td>
                     </tr>
                     <tr>
                        <td>SUM52PE</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                     <tr>
                        <td>SUM52PE</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>SUM44PE</td>
                        <td>+</td>
                        <td>+</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                     <tr>
                        <td>SUM44PE</td>
                        <td>+</td>
                        <td>+/-</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>EVSA-T</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>HER2+</td>
                     </tr>
                     <tr>
                        <td>EVSA-T</td>
                        <td>-</td>
                        <td>+</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>MPE600</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>MPE600</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Legenda: LA – luminalni tip A, LB – luminalni tip B, HER2+, TNRD-A – trojno negativni rak dojk vrste A, TNRD-B – trojno negativni rak dojk vrste B. Tabela 4 je povzeta po Tabeli 3 od Dai in sod. (<xref ref-type="bibr" rid="b5">5</xref>), uporabljeno z licenco CC BY-NC 4.0.</p>
               </table-wrap-foot>
            </table-wrap>
            <p>Zato so raziskave, ki temeljijo na CL in njihovi primerjavi, zahtevne. Prav tako je razumevanje CL slabše in neenotno.</p>
            <p>Ob tem je potrebno poudariti, da je bil velik delež preiskav opravljen v 2D okolju in ne v 3D okolju, ki je boljši približek fiziološkemu tkivu. V večini poskusov na CL v 2D okolju se celice gojijo na rigidnih materialih, kot so poliester ali steklo. Takšne standardne rudimentarne celične enoslojne kulture predstavljajo manj stvarno podobo fiziologije dejanskega tkiva. Izbor materiala in pogojev gojenja bistveno vpliva na tkivno specifično arhitekturo (polarnost, sploščena oblika celic), mehanične/biokemične signale in zato na medcelično komunikacijo (<xref ref-type="bibr" rid="b48">48</xref>). Primerjava med splošnimi značilnostmi 2D in 3D sistema je predstavljena v <xref ref-type="table" rid="table5">Tabeli 5</xref>.</p>
            <table-wrap position="anchor" id="table5">
               <label>Tabela 5:</label>
               <caption>
                  <p> Primerjava med 2D in 3D celičnimi kulturami.</p>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>Kriterij</th>
                        <th>2D</th>
                        <th>3D</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>Morfologija</td>
                        <td>
                           <p>Oblika spremenjena.</p>
                           <p>Polarizacija izgubljena.</p>
                        </td>
                        <td>
                           <p>Realna oblika.</p>
                           <p>Polarizacija ohranjena.</p>
                        </td>
                     </tr>
                     <tr>
                        <td>Genetski profil</td>
                        <td>Geni za celično adhezijo, proliferacijo in preživetje so v primerjavi z <italic>in vivo</italic> spremenjeni.</td>
                        <td>Boljši prikaz rastnih faktorjev, genov za proangiogenezo in adhezijske molekule.</td>
                     </tr>
                     <tr>
                        <td>
                           <p>Celična diferenciacija</p>
                           <p>Morfogeneza</p>
                        </td>
                        <td>Ni spontana.</td>
                        <td>Lahko spontana preko celičnega stika ali zaradi topnih faktorjev.</td>
                     </tr>
                     <tr>
                        <td>Angiogeneza</td>
                        <td>Samo observacijska.</td>
                        <td>Lahko funkcionalna.</td>
                     </tr>
                     <tr>
                        <td>Matematični model</td>
                        <td>Možen.</td>
                        <td>Boljša geometrija, boljša povezava med strukturo in funkcijo.</td>
                     </tr>
                     <tr>
                        <td>Ponovljivost</td>
                        <td>Kratkotrajna.</td>
                        <td>Kontroverzna.</td>
                     </tr>
                     <tr>
                        <td>Stroški</td>
                        <td>Dostopno.</td>
                        <td>Drago.</td>
                     </tr>
                     <tr>
                        <td>Večcelične raziskave</td>
                        <td>Boljše za ugotavljanje imunskega odgovora.</td>
                        <td>Primerno za kombinirano kulturo. Za večje število je zahtevna izvedba.</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Tabela 5 povzeta po Tabeli 1 od Hoarau-Vécho in sod. (<xref ref-type="bibr" rid="b48">48</xref>), uporabljeno z licenco CC BY-NC 4.0.</p>
               </table-wrap-foot>
            </table-wrap>
         </sec>
      </sec>
      <sec id="s4" sec-type="Razprava">
         <label>4</label>
         <title>Razprava</title>
         <p>Z napredkom visoko zmogljive tehnologije (<italic>angl.</italic> high-throughput technology) na področju molekularne genetike se je količina informacij na različnih področjih genomike, razumevanja mehanizmov transkripcije, translacije in epigenetskih mehanizmov neizmerno povečala in postala dostopna za raziskovanje na področju raka. Ob tem se stremi k integraciji informacij na številnih ravneh za razumevanje glavnih funkcionalnih razlik, ki so odgovorne za heterogenost raka. S tem bi lahko omogočili razvoj novih terapevtskih pristopov. V sklopu tega obstajata dva večja trenda; razširitev spektra in števila podtipov, ki so zelo specifični, ob tem pa iskati skupne točke in značilnosti podtipov.</p>
         <p>Kar zadeva same molekularne delitve podtipov RD so Sørlie in sod. postavili standard za intrinzično kategorizacijo. Informativno navajamo, da je v literaturi vendarle tudi moč zaslediti primere drugačnih opredelitev (<xref ref-type="bibr" rid="b10">10</xref>-<xref ref-type="bibr" rid="b12">12</xref>). V raziskavi Sotiriou in sod. so ob uporabi 706 cDNA fragmentov opisali 6 podtipov znotraj skupine RD. Te skupine so bile trije podtipi podobni luminalnemu, en podoben HER2 in dva bazalnemu podtipu podobna podtipa (<xref ref-type="bibr" rid="b49">49</xref>). Drugi primeri so delitev Fana in sod. (uporaba 70 genskih signatur) v 4 podtipe, v katerih je bil odsoten normalnemu podoben podtip (LA, LB, čezmerna izraženost HER2, bazalni) (<xref ref-type="bibr" rid="b50">50</xref>); v raziskavi Lehmann in sod. so razdelili TNRD v 6 skupin (dva bazalnemu podobne (BL1 in BL2), en imunomodulacijski (IM), en mezenhimski (M), en mezenhimski <italic>stem-like</italic> (MSL) in en luminalni androgenski receptor (LAR) podtip (<xref ref-type="bibr" rid="b51">51</xref>).</p>
         <p>Prav tako je potrebno omeniti, da je primerljivost raziskav in rezultatov na CL RD težja zaradi množičnega števila raziskav in pristajanja na enotno poimenovanje. Dai in sod. v svojem prispevku navaja številne raziskave: Charafe-Jauffret in sod. (<xref ref-type="bibr" rid="b31">31</xref>), Riaz in sod. (<xref ref-type="bibr" rid="b25">25</xref>), Lehmann in sod. (<xref ref-type="bibr" rid="b51">51</xref>) so vsi uporabili drugačne klasifikacije (<xref ref-type="bibr" rid="b5">5</xref>). Poleg različnih klasifikacij so prav tako tudi prisotne razlike v molekularni karakterizaciji. Številni avtorji so prav tako omenili problematiko preobširne in nestandardizirane, nenadzorovane uporabe CL (<xref ref-type="bibr" rid="b52">52</xref>) in dilemo o prenosljivosti dognanj na CL v klinično okolje (<xref ref-type="bibr" rid="b45">45</xref>,<xref ref-type="bibr" rid="b53">53</xref>). Čeprav so tkiva v večinskem deležu identična glede na glavno določitev receptorskega statusa in statusa HER2, je v zadnjem času vedno več znanega o naknadnih drastičnih genetskih in epigenetskih spremembah v sklopu gojenja linije v laboratorijskem okolju. Zato ostaja odprto vprašanje o primerljivosti molekularnih značilnosti, heterogenosti RD in CL (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b45">45</xref>). Klonalna populacija ene CL ne more dodobra prikazati raznolikosti procesov na ravni znotraj tumorja. Karcinogeneza je večstopenjski proces, ki vključuje mnogo kliničnih in patoloških stopenj. Med te sodijo tipična hiperproliferacija, lokalna invazija, tvorba invazivnega karcinoma in v končni fazi razsoj bolezni. Ta proces spremljajo postopne pridobitve različnih vrst genetskih in epigenetskih mutacij celic, ki jim sledijo klonalna selekcija in ekspanzija. V fazi kultiviranja CL lahko pride do odstranitve določenega tipa celic, ki so sprva prisotne v tkivu, vendar se zaradi dejavnikov okolja ne morejo razviti. Vzroki so lahko v porušenem mikrookolju ali pomanjkanju posebnih rastnih dejavnikov. Zato lahko pride do njihovega propada in s tem spremembe heterogenosti tumorja. Primer tega so celice, ki na plastični površini ali sploh ne rastejo oz. brez dodatka specifičnih dejavnikov iz tumorskega mikrookolja ne morejo uspevati, zato odmrejo. Torej se poraja vprašanje, ali je potencialna CL, ki bi lahko služila kot model tumorja in ob tem ohranjala vso heterogenost, sploh mogoča. Omenili so tudi problematiko kontaminacij. Izvor kontaminacij CL je več: nekakovosten način vzgajanja CL, neprimerna kontrola kakovosti, napake uporabnika pri poimenovanju, aerosolni transfer celic ipd. (<xref ref-type="bibr" rid="b52">52</xref>,<xref ref-type="bibr" rid="b54">54</xref>-<xref ref-type="bibr" rid="b56">56</xref>).</p>
         <p>Pomisleki in izbira vrste (2D ali 3D, <italic>in vitro</italic> ali <italic>in vivo</italic>) gojenja CL je odvisna od primarnega namena raziskave. Ob tem se je potrebno zavedati prednosti in pomanjkljivosti različnih v prispevku opisanih načinov. Kljub določenim pomanjkljivostim ostaja dejstvo, da so CL izrednega pomena za raziskovanje karcinogeneze kot tudi novih načinov zdravljenja. Ob tem pa je za zagotavljanje neoporečnosti raziskav nujno standardizirano potrjevanje CL (<xref ref-type="bibr" rid="b53">53</xref>). Priporočljivo je svoje vzorce pred uporabo pregledati in preveriti za navzkrižne kontaminacije in verodostojnost linije. Derivacija novih CL naj spremlja določanje genske sorodnosti s primarnim tkivom s STR profiliranjem genskega zapisa primarnega tkiva in CL. Prav tako se naj v sklopu karakteriziranja in primerjave pregledajo histološki in fenotipski označevalci.</p>
         <p>Področje gojenja CL se hitro razvija. Utemeljeno domnevamo, da se bo z novejšimi raziskovalnimi metodami (molekularna genetika, proteomika ipd.) lahko še bolje opredelila narava RD.</p>
      </sec>
      <sec id="s5" sec-type="Zahvale">
         <label>5</label>
         <title>Zahvale</title>
         <p>Avtorji se zahvaljujemo za sofinanciranje raziskave Javni agenciji za raziskovalno dejavnost RS (pogodbe: P3–0036, I0–0029 in J3–9272) in Univerzitetnemu kliničnemu centru Maribor (pogodba: IRP 2018/01–10).</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ferlay</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Soerjomataram</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dikshit</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eser</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mathers</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rebelo</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</article-title>. 
                    <source>Int J Cancer</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>136</volume>(
                    <issue>5</issue>):
                    <fpage>E359</fpage>–
                    <lpage>86</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id>
                    <pub-id pub-id-type="pmid">25220842</pub-id>
                    <issn>0020-7136</issn>
                </mixed-citation>
         </ref>
         <ref id="b2">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zadnik</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Primic Zakelj</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lokar</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jarm</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ivanus</surname>
                     <given-names>U</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zagar</surname>
                     <given-names>T</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cancer burden in slovenia with the time trends analysis</article-title>. 
                    <source>Radiol Oncol</source>. 
                    <year>2017</year>
                    <month>Feb</month>;
                    <volume>51</volume>(
                    <issue>1</issue>):
                    <fpage>47</fpage>–
                    <lpage>55</lpage>. 
                    <pub-id pub-id-type="doi">10.1515/raon-2017-0008</pub-id>
                    <pub-id pub-id-type="pmid">28265232</pub-id>
                    <issn>1318-2099</issn>
                </mixed-citation>
         </ref>
         <ref id="b3">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dawood</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Broglio</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Buzdar</surname>
                     <given-names>AU</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hortobagyi</surname>
                     <given-names>GN</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Giordano</surname>
                     <given-names>SH</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review</article-title>. 
                    <source>J Clin Oncol</source>. 
                    <year>2010</year>
                    <month>Jan</month>;
                    <volume>28</volume>(
                    <issue>1</issue>):
                    <fpage>92</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1200/JCO.2008.19.9844</pub-id>
                    <pub-id pub-id-type="pmid">19933921</pub-id>
                    <issn>0732-183X</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Brenton</surname>
                     <given-names>JD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Carey</surname>
                     <given-names>LA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ahmed</surname>
                     <given-names>AA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Caldas</surname>
                     <given-names>C</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Molecular classification and molecular forecasting of breast cancer: ready for clinical application?</article-title>
                    <source>J Clin Oncol</source>. 
                    <year>2005</year>
                    <month>Oct</month>;
                    <volume>23</volume>(
                    <issue>29</issue>):
                    <fpage>7350</fpage>–
                    <lpage>60</lpage>. 
                    <pub-id pub-id-type="doi">10.1200/JCO.2005.03.3845</pub-id>
                    <pub-id pub-id-type="pmid">16145060</pub-id>
                    <issn>0732-183X</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dai</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cheng</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bai</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Li</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Breast cancer cell line classification and its relevance with breast tumor subtyping</article-title>. 
                    <source>J Cancer</source>. 
                    <year>2017</year>
                    <month>Sep</month>;
                    <volume>8</volume>(
                    <issue>16</issue>):
                    <fpage>3131</fpage>–
                    <lpage>41</lpage>. 
                    <pub-id pub-id-type="doi">10.7150/jca.18457</pub-id>
                    <pub-id pub-id-type="pmid">29158785</pub-id>
                    <issn>0378-2360</issn>
                </mixed-citation>
         </ref>
         <ref id="b6">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Cope</surname>
                     <given-names>LM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fackler</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lopez-Bujanda</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wolff</surname>
                     <given-names>AC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Visvanathan</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gray</surname>
                     <given-names>JW</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Do breast cancer cell lines provide a relevant model of the patient tumor methylome?</article-title>.
                    <source>PLoS One</source>. 
                    <year>2014</year>; 
                    <volume>9</volume>(
                    <issue>8</issue>):
                    <fpage>e105545</fpage>. 
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0105545</pub-id> 
                    <pub-id pub-id-type="pmid">25157401</pub-id>
                    <issn>1932-6203</issn> 
                </mixed-citation>
         </ref>
         <ref id="b7">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Chavez</surname>
                     <given-names>KJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Garimella</surname>
                     <given-names>SV</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lipkowitz</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>.
                    <article-title>Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer</article-title>.
                    <source>Breast Dis</source>. 
                    <year>2010</year>; 
                    <volume>32</volume>(
                    <issue>1-2</issue>):
                    <fpage>35</fpage>-
                    <lpage>48</lpage>.
                    <pub-id pub-id-type="doi">doi: 10.1371/journal.pone.0105545</pub-id> 
                    <pub-id pub-id-type="pmid">25157401</pub-id>
                    <issn>1932-6203</issn> 
                </mixed-citation>
         </ref>
         <ref id="b8">
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ellis</surname>
                     <given-names>IO</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Collins</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ichihara</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>MacGrogan</surname>
                     <given-names>G</given-names>
                  </name>
                    </person-group>. 
                    <chapter-title>Invasive carcinoma of no special type</chapter-title>. In: 
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Lakhani</surname>
                     <given-names>SR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Elis</surname>
                     <given-names>IO</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schnitt</surname>
                     <given-names>SJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tan</surname>
                     <given-names>PH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vijver</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <role>eds</role>
                    </person-group>. 
                    <source>WHO classification of Tumours of the Breast</source>. 
                    <publisher-loc>Lyon</publisher-loc>: 
                    <publisher-name>IARC</publisher-name>; 
                    <year>2012</year>.
                </mixed-citation>
         </ref>
         <ref id="b9">
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lakhani</surname>
                     <given-names>SR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rakha</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Simpson</surname>
                     <given-names>PT</given-names>
                  </name>
                    </person-group>. 
                    <chapter-title>Special subtypes</chapter-title>. In: 
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Lakhani</surname>
                     <given-names>SR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Elis</surname>
                     <given-names>IO</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schnitt</surname>
                     <given-names>SJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tan</surname>
                     <given-names>PH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vijver</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <role>eds</role>
                    </person-group>. 
                    <source>WHO classification of tumours of the breast</source>. 
                    <publisher-loc>Lyon</publisher-loc>: 
                    <publisher-name>IARC</publisher-name>; 
                    <year>2012</year>.
                </mixed-citation>
         </ref>
         <ref id="b10">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Perou</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sorlie</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eisen</surname>
                     <given-names>MB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>van de Rijn</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jeffrey</surname>
                     <given-names>SS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rees</surname>
                     <given-names>CA</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Molecular portraits of human breast tumours</article-title>. 
                    <source>Nature</source>. 
                    <year>2000</year>
                    <month>Aug</month>;
                    <volume>406</volume>(
                    <issue>6797</issue>):
                    <fpage>747</fpage>–
                    <lpage>52</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/35021093</pub-id>
                    <pub-id pub-id-type="pmid">10963602</pub-id>
                    <issn>0028-0836</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sorlie</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Perou</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tibshirani</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Aas</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Geisler</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Johnsen</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title>. 
                    <source>Proc Natl Acad Sci USA</source>. 
                    <year>2001</year>
                    <month>Sep</month>;
                    <volume>98</volume>(
                    <issue>19</issue>):
                    <fpage>10869</fpage>–
                    <lpage>74</lpage>. 
                    <pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id>
                    <pub-id pub-id-type="pmid">11553815</pub-id>
                    <issn>0027-8424</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sorlie</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tibshirani</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Parker</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hastie</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Marron</surname>
                     <given-names>JS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nobel</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Repeated observation of breast tumor subtypes in independent gene expression data sets</article-title>. 
                    <source>Proc Natl Acad Sci USA</source>. 
                    <year>2003</year>
                    <month>Jul</month>;
                    <volume>100</volume>(
                    <issue>14</issue>):
                    <fpage>8418</fpage>–
                    <lpage>23</lpage>. 
                    <pub-id pub-id-type="doi">10.1073/pnas.0932692100</pub-id>
                    <pub-id pub-id-type="pmid">12829800</pub-id>
                    <issn>0027-8424</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Cheang</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chia</surname>
                     <given-names>SK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Voduc</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gao</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Leung</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Snider</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>2009</year>
                    <month>May</month>;
                    <volume>101</volume>(
                    <issue>10</issue>):
                    <fpage>736</fpage>–
                    <lpage>50</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/jnci/djp082</pub-id>
                    <pub-id pub-id-type="pmid">19436038</pub-id>
                    <issn>0027-8874</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Smid</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhang</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sieuwerts</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yu</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Klijn</surname>
                     <given-names>JG</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Subtypes of breast cancer show preferential site of relapse</article-title>. 
                    <source>Cancer Res</source>. 
                    <year>2008</year>
                    <month>May</month>;
                    <volume>68</volume>(
                    <issue>9</issue>):
                    <fpage>3108</fpage>–
                    <lpage>14</lpage>. 
                    <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5644</pub-id>
                    <pub-id pub-id-type="pmid">18451135</pub-id>
                    <issn>0008-5472</issn>
                </mixed-citation>
         </ref>
         <ref id="b15">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dai</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Li</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bai</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yang</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Liu</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhan</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Breast cancer intrinsic subtype classification, clinical use and future trends</article-title>. 
                    <source>Am J Cancer Res</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>5</volume>(
                    <issue>10</issue>):
                    <fpage>2929</fpage>–
                    <lpage>43</lpage>.
                    <pub-id pub-id-type="pmid">26693050</pub-id>
                    <issn>2156-6976</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hole</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pedersen</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hansen</surname>
                     <given-names>SK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lundqvist</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yde</surname>
                     <given-names>CW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lykkesfeldt</surname>
                     <given-names>AE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane</article-title>. 
                    <source>Int J Oncol</source>. 
                    <year>2015</year>
                    <month>Apr</month>;
                    <volume>46</volume>(
                    <issue>4</issue>):
                    <fpage>1481</fpage>–
                    <lpage>90</lpage>. 
                    <pub-id pub-id-type="doi">10.3892/ijo.2015.2850</pub-id>
                    <pub-id pub-id-type="pmid">25625755</pub-id>
                    <issn>1019-6439</issn>
                </mixed-citation>
         </ref>
         <ref id="b17">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Holen</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Speirs</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Morrissey</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blyth</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>
                        <italic toggle="yes">In vivo</italic> models in breast cancer research: progress, challenges and future directions </article-title>. 
                    <source>Dis Model Mech</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>10</volume>(
                    <issue>4</issue>):
                    <fpage>359</fpage>–
                    <lpage>71</lpage>. 
                    <pub-id pub-id-type="doi">10.1242/dmm.028274</pub-id>
                    <pub-id pub-id-type="pmid">28381598</pub-id>
                    <issn>1754-8403</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Holliday</surname>
                     <given-names>DL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Speirs</surname>
                     <given-names>V</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Choosing the right cell line for breast cancer research</article-title>. 
                    <source>Breast Cancer Res</source>. 
                    <year>2011</year>
                    <month>Aug</month>;
                    <volume>13</volume>(
                    <issue>4</issue>):
                    <fpage>215</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/bcr2889</pub-id>
                    <pub-id pub-id-type="pmid">21884641</pub-id>
                    <issn>1465-5411</issn>
                </mixed-citation>
         </ref>
         <ref id="b19">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Greely</surname>
                     <given-names>HT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cho</surname>
                     <given-names>MK</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The Henrietta Lacks legacy grows</article-title>. 
                    <source>EMBO Rep</source>. 
                    <year>2013</year>
                    <month>Oct</month>;
                    <volume>14</volume>(
                    <issue>10</issue>):
                    <fpage>849</fpage>. 
                    <pub-id pub-id-type="doi">10.1038/embor.2013.148</pub-id>
                    <pub-id pub-id-type="pmid">24030280</pub-id>
                    <issn>1469-221X</issn>
                </mixed-citation>
         </ref>
         <ref id="b20">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lasfargues</surname>
                     <given-names>EY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ozzello</surname>
                     <given-names>L</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cultivation of human breast carcinomas</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>1958</year>
                    <month>Dec</month>;
                    <volume>21</volume>(
                    <issue>6</issue>):
                    <fpage>1131</fpage>–
                    <lpage>47</lpage>.
                    <pub-id pub-id-type="pmid">13611537</pub-id>
                    <issn>0027-8874</issn>
                </mixed-citation>
         </ref>
         <ref id="b21">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Amadori</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bertoni</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Flamigni</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Savini</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>De Giovanni</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Casanova</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Establishment and characterization of a new cell line from primary human breast carcinoma</article-title>. 
                    <source>Breast Cancer Res Treat</source>. 
                    <year>1993</year>
                    <month>Dec</month>;
                    <volume>28</volume>(
                    <issue>3</issue>):
                    <fpage>251</fpage>–
                    <lpage>60</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/BF00666586</pub-id>
                    <pub-id pub-id-type="pmid">8018954</pub-id>
                    <issn>0167-6806</issn>
                </mixed-citation>
         </ref>
         <ref id="b22">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gazdar</surname>
                     <given-names>AF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kurvari</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Virmani</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gollahon</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sakaguchi</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Westerfield</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer</article-title>. 
                    <source>Int J Cancer</source>. 
                    <year>1998</year>
                    <month>Dec</month>;
                    <volume>78</volume>(
                    <issue>6</issue>):
                    <fpage>766</fpage>–
                    <lpage>74</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19981209)78:6&lt;766::AID-IJC15&gt;3.0.CO;2-L</pub-id>
                    <pub-id pub-id-type="pmid">9833771</pub-id>
                    <issn>0020-7136</issn> 
                </mixed-citation>
         </ref>
         <ref id="b23">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lee</surname>
                     <given-names>AV</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Oesterreich</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Davidson</surname>
                     <given-names>NE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>MCF-7 cells—changing the course of breast cancer research and care for 45 years</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>107</volume>(
                    <issue>7</issue>):
                    <fpage>djv073</fpage>–
                    <lpage>073</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/jnci/djv073</pub-id>
                    <pub-id pub-id-type="pmid">25828948</pub-id>
                    <issn>0027-8874</issn>
                </mixed-citation>
         </ref>
         <ref id="b24">
            <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>International Cell Line Authentication Committee</collab>
                    </person-group>. 
                    <source>Naming a Cell Line - ver. 1.6.</source>.
                    <year>2015</year>. 
                    <date-in-citation content-type="access-date" iso-8601-date="2018-04-14">[cited 2018 Apr 18]</date-in-citation> 
                    <comment>Available from:<uri>http://iclac.org/wp-content/uploads/Naming-a-Cell-Line_v1_6.pdf</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b25">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Riaz</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>van Jaarsveld</surname>
                     <given-names>MT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hollestelle</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Prager-van der Smissen</surname>
                     <given-names>WJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Heine</surname>
                     <given-names>AA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Boersma</surname>
                     <given-names>AW</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs</article-title>. 
                    <source>Breast Cancer Res</source>. 
                    <year>2013</year>
                    <month>Apr</month>;
                    <volume>15</volume>(
                    <issue>2</issue>):
                    <fpage>R33</fpage>–
                    <lpage>33</lpage>. 
                    <pub-id pub-id-type="doi">10.1186/bcr3415</pub-id>
                    <pub-id pub-id-type="pmid">23601657</pub-id>
                    <issn>1465-5411</issn>
                </mixed-citation>
         </ref>
         <ref id="b26">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Waks</surname>
                     <given-names>AG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Winer</surname>
                     <given-names>EP</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Breast Cancer Treatment: A Review</article-title>. 
                    <source>JAMA</source>. 
                    <year>2019</year>
                    <month>Jan</month>;
                    <volume>321</volume>(
                    <issue>3</issue>):
                    <fpage>288</fpage>–
                    <lpage>300</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jama.2018.19323</pub-id>
                    <pub-id pub-id-type="pmid">30667505</pub-id>
                    <issn>0098-7484</issn>
                </mixed-citation>
         </ref>
         <ref id="b27">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bertucci</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Borie</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ginestier</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Groulet</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Charafe-Jauffret</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Adélaide</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Identification and validation of an ERBB2 gene expression signature in breast cancers</article-title>. 
                    <source>Oncogene</source>. 
                    <year>2004</year>
                    <month>Apr</month>;
                    <volume>23</volume>(
                    <issue>14</issue>):
                    <fpage>2564</fpage>–
                    <lpage>75</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj.onc.1207361</pub-id>
                    <pub-id pub-id-type="pmid">14743203</pub-id>
                    <issn>0950-9232</issn>
                </mixed-citation>
         </ref>
         <ref id="b28">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sahlberg</surname>
                     <given-names>KK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hongisto</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Edgren</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mäkelä</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hellström</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Due</surname>
                     <given-names>EU</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells</article-title>. 
                    <article-title>Mol Oncol</article-title>. 
                    <year>2013</year>;
                    <volume>7</volume>(
                    <issue>3</issue>):
                    <fpage>392</fpage>–
                    <lpage>401</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.molonc.2012.10.012</pub-id> 
                    <pub-id pub-id-type="pmid">23253899</pub-id>
                    <issn>1574-7891</issn> 
                </mixed-citation>
         </ref>
         <ref id="b29">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Neve</surname>
                     <given-names>RM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chin</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fridlyand</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yeh</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Baehner</surname>
                     <given-names>FL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fevr</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes</article-title>. 
                    <source>Cancer Cell</source>. 
                    <year>2006</year>
                    <month>Dec</month>;
                    <volume>10</volume>(
                    <issue>6</issue>):
                    <fpage>515</fpage>–
                    <lpage>27</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.008</pub-id>
                    <pub-id pub-id-type="pmid">17157791</pub-id>
                    <issn>1535-6108</issn>
                </mixed-citation>
         </ref>
         <ref id="b30">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kao</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Salari</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bocanegra</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Choi</surname>
                     <given-names>YL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Girard</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gandhi</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery</article-title>.
                    <source>PLoS One</source>. 
                    <year>2009</year>.
                    <volume>4</volume>(
                    <issue>7</issue>):
                    <fpage>e6146</fpage>
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0006146</pub-id>
                    <pub-id pub-id-type="pmid">19582160</pub-id>
                    <issn>1932-6203</issn> 
                </mixed-citation>
         </ref>
         <ref id="b31">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Charafe-Jauffret</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ginestier</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Monville</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Finetti</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Adélaide</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cervera</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Gene expression profiling of breast cell lines identifies potential new basal markers</article-title>. 
                    <source>Oncogene</source>. 
                    <year>2006</year>
                    <month>Apr</month>;
                    <volume>25</volume>(
                    <issue>15</issue>):
                    <fpage>2273</fpage>–
                    <lpage>84</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj.onc.1209254</pub-id>
                    <pub-id pub-id-type="pmid">16288205</pub-id>
                    <issn>0950-9232</issn>
                </mixed-citation>
         </ref>
         <ref id="b32">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lu</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Takai</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weaver</surname>
                     <given-names>VM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Werb</surname>
                     <given-names>Z</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Extracellular matrix degradation and remodeling in development and disease</article-title>. 
                    <source>Cold Spring Harb Perspect Biol</source>. 
                    <year>2011</year>
                    <month>Dec</month>;
                    <volume>3</volume>(
                    <issue>12</issue>):
                    <fpage>a005058</fpage>. 
                    <pub-id pub-id-type="doi">10.1101/cshperspect.a005058</pub-id>
                    <pub-id pub-id-type="pmid">21917992</pub-id>
                    <issn>1943-0264</issn>
                </mixed-citation>
         </ref>
         <ref id="b33">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dai</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Xiang</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Li</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bai</surname>
                     <given-names>Z</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cancer hallmarks, biomarkers and breast cancer molecular subtypes</article-title>. 
                    <source>J Cancer</source>. 
                    <year>2016</year>
                    <month>Jun</month>;
                    <volume>7</volume>(
                    <issue>10</issue>):
                    <fpage>1281</fpage>–
                    <lpage>94</lpage>. 
                    <pub-id pub-id-type="doi">10.7150/jca.13141</pub-id>
                    <pub-id pub-id-type="pmid">27390604</pub-id>
                    <issn>0378-2360</issn>
                </mixed-citation>
         </ref>
         <ref id="b34">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Elledge</surname>
                     <given-names>SJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage</article-title>. 
                    <source>Proc Natl Acad Sci USA</source>. 
                    <year>2007</year>
                    <month>Dec</month>;
                    <volume>104</volume>(
                    <issue>52</issue>):
                    <fpage>20759</fpage>–
                    <lpage>63</lpage>. 
                    <pub-id pub-id-type="doi">10.1073/pnas.0710061104</pub-id>
                    <pub-id pub-id-type="pmid">18077395</pub-id>
                    <issn>0027-8424</issn>
                </mixed-citation>
         </ref>
         <ref id="b35">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gradisnik</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Trapecar</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rupnik</surname>
                     <given-names>MS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Velnar</surname>
                     <given-names>T</given-names>
                  </name>
                    </person-group>. 
                    <article-title>HUIEC, Human intestinal epithelial cell line with differentiated properties: process of isolation and characterisation</article-title>. 
                    <source>Wien Klin Wochenschr</source>. 
                    <year>2015</year>
                    <month>Dec</month>;
                    <volume>127</volume>(
                    <issue>S5</issue>
                    <supplement>Suppl 5</supplement>):
                    <fpage>S204</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00508-015-0771-1</pub-id>
                    <pub-id pub-id-type="pmid">25821058</pub-id>
                    <issn>0043-5325</issn>
                </mixed-citation>
         </ref>
         <ref id="b36">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Naranda</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gradišnik</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gorenjak</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vogrin</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maver</surname>
                     <given-names>U</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Isolation and characterization of human articular chondrocytes from surgical waste after total knee arthroplasty (TKA)</article-title>. 
                    <source>PeerJ</source>. 
                    <year>2017</year>
                    <month>Mar</month>;
                    <volume>5</volume>:
                    <fpage>e3079</fpage>. 
                    <pub-id pub-id-type="doi">10.7717/peerj.3079</pub-id>
                    <pub-id pub-id-type="pmid">28344902</pub-id>
                    <issn>2167-8359</issn> 
                </mixed-citation>
         </ref>
         <ref id="b37">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lacroix</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Haibe-Kains</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hennuy</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Laes</surname>
                     <given-names>JF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lallemand</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gonze</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes</article-title>. 
                    <source>Oncol Rep</source>. 
                    <year>2004</year>
                    <month>Oct</month>;
                    <volume>12</volume>(
                    <issue>4</issue>):
                    <fpage>701</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.3892/or.12.4.701</pub-id>
                    <pub-id pub-id-type="pmid">15375488</pub-id>
                    <issn>1021-335X</issn>
                </mixed-citation>
         </ref>
         <ref id="b38">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hiscox</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Baruha</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Smith</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bellerby</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goddard</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jordan</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan</article-title>. 
                    <source>BMC Cancer</source>. 
                    <year>2012</year>
                    <month>Oct</month>;
                    <volume>12</volume>(
                    <issue>1</issue>):
                    <fpage>458</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/1471-2407-12-458</pub-id>
                    <pub-id pub-id-type="pmid">23039365</pub-id>
                    <issn>1471-2407</issn>
                </mixed-citation>
         </ref>
         <ref id="b39">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Larramendy</surname>
                     <given-names>ML</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lushnikova</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Björkqvist</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wistuba</surname>
                     <given-names>II</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Virmani</surname>
                     <given-names>AK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Shivapurkar</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines</article-title>. 
                    <source>Cancer Genet Cytogenet</source>. 
                    <year>2000</year>
                    <month>Jun</month>;
                    <volume>119</volume>(
                    <issue>2</issue>):
                    <fpage>132</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0165-4608(99)00226-5</pub-id>
                    <pub-id pub-id-type="pmid">10867149</pub-id>
                    <issn>0165-4608</issn>
                </mixed-citation>
         </ref>
         <ref id="b40">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Nestor</surname>
                     <given-names>CE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ottaviano</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Reinhardt</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cruickshanks</surname>
                     <given-names>HA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mjoseng</surname>
                     <given-names>HK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>McPherson</surname>
                     <given-names>RC</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems</article-title>. 
                    <source>Genome Biol</source>. 
                    <year>2015</year>
                    <month>Feb</month>;
                    <volume>16</volume>(
                    <issue>1</issue>):
                    <fpage>11</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/s13059-014-0576-y</pub-id>
                    <pub-id pub-id-type="pmid">25648825</pub-id>
                    <issn>1474-7596</issn>
                </mixed-citation>
         </ref>
         <ref id="b41">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Widschwendter</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jones</surname>
                     <given-names>PA</given-names>
                  </name>
                    </person-group>. 
                    <article-title>DNA methylation and breast carcinogenesis</article-title>. 
                    <source>Oncogene</source>. 
                    <year>2002</year>
                    <month>Aug</month>;
                    <volume>21</volume>(
                    <issue>35</issue>):
                    <fpage>5462</fpage>–
                    <lpage>82</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj.onc.1205606</pub-id>
                    <pub-id pub-id-type="pmid">12154408</pub-id>
                    <issn>0950-9232</issn>
                </mixed-citation>
         </ref>
         <ref id="b42">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kapałczyńska</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kolenda</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Przybyła</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zajączkowska</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Teresiak</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Filas</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>..
                    <article-title>2D and 3D cell cultures - a comparison of different types of cancer cell cultures</article-title>. 
                    <source>Arch Med Sci</source>. 
                    <year>2018</year>;
                    <volume>14</volume>(
                    <issue>14</issue>):
                    <fpage>910</fpage>-
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.5114/aoms.2016.63743</pub-id>
                    <pub-id pub-id-type="pmid">30002710</pub-id>
                    <issn>1734-1922</issn> 
                </mixed-citation>
         </ref>
         <ref id="b43">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hsieh</surname>
                     <given-names>C-H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chen</surname>
                     <given-names>Y-D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Huang</surname>
                     <given-names>S-F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>H-M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wu</surname>
                     <given-names>M-H</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The effect of primary cancer cell culture models on the results of drug chemosensitivity assays: the application of perfusion microbioreactor system as cell culture vessel</article-title>.
                    <source>Biomed Res Int</source>. 
                    <year>2015</year>;
                    <volume>2015</volume>:
                    <fpage>470283</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2015/470283</pub-id> 
                    <pub-id pub-id-type="pmid">25654105</pub-id>
                    <issn>2314-6133</issn> 
                </mixed-citation>
         </ref>
         <ref id="b44">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bulysheva</surname>
                     <given-names>AA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bowlin</surname>
                     <given-names>GL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Petrova</surname>
                     <given-names>SP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yeudall</surname>
                     <given-names>WA</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Enhanced chemoresistance of squamous carcinoma cells grown in 3D cryogenic electrospun scaffolds</article-title>. 
                    <source>Biomed Mater</source>. 
                    <year>2013</year>
                    <month>Oct</month>;
                    <volume>8</volume>(
                    <issue>5</issue>):
                    <fpage>055009</fpage>. 
                    <pub-id pub-id-type="doi">10.1088/1748-6041/8/5/055009</pub-id>
                    <pub-id pub-id-type="pmid">24057893</pub-id>
                    <issn>1748-6041</issn>
                </mixed-citation>
         </ref>
         <ref id="b45">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fackler</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lopez Bujanda</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Umbricht</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Teo</surname>
                     <given-names>WW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cho</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhang</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer</article-title>. 
                    <source>Cancer Res</source>. 
                    <year>2014</year>
                    <month>Apr</month>;
                    <volume>74</volume>(
                    <issue>8</issue>):
                    <fpage>2160</fpage>–
                    <lpage>70</lpage>. 
                    <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-3392</pub-id>
                    <pub-id pub-id-type="pmid">24737128</pub-id>
                    <issn>0008-5472</issn>
                </mixed-citation>
         </ref>
         <ref id="b46">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Christgen</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lehmann</surname>
                     <given-names>U</given-names>
                  </name>
                    </person-group>. 
                    <article-title>MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing</article-title>. 
                    <source>Cancer Biol Ther</source>. 
                    <year>2007</year>
                    <month>Sep</month>;
                    <volume>6</volume>(
                    <issue>9</issue>):
                    <fpage>1355</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.4161/cbt.6.9.4624</pub-id>
                    <pub-id pub-id-type="pmid">17786032</pub-id>
                    <issn>1538-4047</issn>
                </mixed-citation>
         </ref>
         <ref id="b47">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dvořánková</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Szabo</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lacina</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kodet</surname>
                     <given-names>O</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matoušková</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Smetana</surname>
                     <given-names>K</given-names>
                     <suffix>Jr</suffix>
                  </name>
                    </person-group>. 
                    <article-title>Fibroblasts prepared from different types of malignant tumors stimulate expression of luminal marker keratin 8 in the EM-G3 breast cancer cell line</article-title>. 
                    <source>Histochem Cell Biol</source>. 
                    <year>2012</year>
                    <month>May</month>;
                    <volume>137</volume>(
                    <issue>5</issue>):
                    <fpage>679</fpage>–
                    <lpage>85</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00418-012-0918-3</pub-id>
                    <pub-id pub-id-type="pmid">22270320</pub-id>
                    <issn>0948-6143</issn>
                </mixed-citation>
         </ref>
         <ref id="b48">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hoarau-Véchot</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rafii</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Touboul</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pasquier</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Halfway between 2D and ANIMAL MODELS: Are 3D cultures the ideal tool to study cancer-microenvironment interactions?</article-title>.
                    <source>Int J Mol Sci</source>. 
                    <year>2018</year>
                    <month>Jan</month>;
                    <volume>19</volume>(
                    <issue>1</issue>):
                    <fpage>181</fpage>. 
                    <pub-id pub-id-type="doi">10.3390/ijms19010181</pub-id>
                    <pub-id pub-id-type="pmid">29346265</pub-id>
                    <issn>1661-6596</issn>
                </mixed-citation>
         </ref>
         <ref id="b49">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sotiriou</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Neo</surname>
                     <given-names>SY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>McShane</surname>
                     <given-names>LM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Korn</surname>
                     <given-names>EL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Long</surname>
                     <given-names>PM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jazaeri</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Breast cancer classification and prognosis based on gene expression profiles from a population-based study</article-title>. 
                    <source>Proc Natl Acad Sci USA</source>. 
                    <year>2003</year>
                    <month>Sep</month>;
                    <volume>100</volume>(
                    <issue>18</issue>):
                    <fpage>10393</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1073/pnas.1732912100</pub-id>
                    <pub-id pub-id-type="pmid">12917485</pub-id>
                    <issn>0027-8424</issn>
                </mixed-citation>
         </ref>
         <ref id="b50">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fan</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Oh</surname>
                     <given-names>DS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wessels</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weigelt</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nuyten</surname>
                     <given-names>DS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nobel</surname>
                     <given-names>AB</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Concordance among gene-expression-based predictors for breast cancer</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2006</year>
                    <month>Aug</month>;
                    <volume>355</volume>(
                    <issue>6</issue>):
                    <fpage>560</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa052933</pub-id>
                    <pub-id pub-id-type="pmid">16899776</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
         </ref>
         <ref id="b51">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lehmann</surname>
                     <given-names>BD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bauer</surname>
                     <given-names>JA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chen</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sanders</surname>
                     <given-names>ME</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chakravarthy</surname>
                     <given-names>AB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Shyr</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</article-title>. 
                    <source>J Clin Invest</source>. 
                    <year>2011</year>
                    <month>Jul</month>;
                    <volume>121</volume>(
                    <issue>7</issue>):
                    <fpage>2750</fpage>–
                    <lpage>67</lpage>. 
                    <pub-id pub-id-type="doi">10.1172/JCI45014</pub-id>
                    <pub-id pub-id-type="pmid">21633166</pub-id>
                    <issn>0021-9738</issn>
                </mixed-citation>
         </ref>
         <ref id="b52">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hynds</surname>
                     <given-names>RE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vladimirou</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Janes</surname>
                     <given-names>SM</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The secret lives of cancer cell lines</article-title>. 
                    <source>Dis Model Mech</source>. 
                    <year>2018</year>
                    <month>Nov</month>;
                    <volume>11</volume>(
                    <issue>11</issue>):
                    <fpage>dmm037366</fpage>. 
                    <pub-id pub-id-type="doi">10.1242/dmm.037366</pub-id>
                    <pub-id pub-id-type="pmid">30459183</pub-id>
                    <issn>1754-8403</issn>
                </mixed-citation>
         </ref>
         <ref id="b53">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Korch</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Spillman</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jackson</surname>
                     <given-names>TA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jacobsen</surname>
                     <given-names>BM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Murphy</surname>
                     <given-names>SK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lessey</surname>
                     <given-names>BA</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination</article-title>.
                    <source>Gynecol Oncol</source>. 
                    <year>2012</year>;
                    <volume>127</volume>(
                    <issue>1</issue>):
                    <fpage>241</fpage>-
                    <lpage>8</lpage> 
                    <pub-id pub-id-type="doi">10.1016/j.ygyno.2012.06.017</pub-id>.
                    <pub-id pub-id-type="pmid">22710073</pub-id>
                    <issn>0090-8258</issn>
                </mixed-citation>
         </ref>
         <ref id="b54">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gillet</surname>
                     <given-names>J-P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Varma</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gottesman</surname>
                     <given-names>MM</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The clinical relevance of cancer cell lines</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>2013</year>;
                    <volume>105</volume>(
                    <issue>7</issue>):
                    <fpage>452</fpage>-
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/jnci/djt007</pub-id>.
                    <pub-id pub-id-type="pmid">23434901</pub-id>
                    <issn>0027-8874</issn> 
                </mixed-citation>
         </ref>
         <ref id="b55">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Wilding</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bodmer</surname>
                     <given-names>WF</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cancer cell lines for drug discovery and development</article-title>. 
                    <source>Cancer Res</source>. 
                    <year>2014</year>
                    <month>May</month>;
                    <volume>74</volume>(
                    <issue>9</issue>):
                    <fpage>2377</fpage>–
                    <lpage>84</lpage>. 
                    <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2971</pub-id> 
                    <pub-id pub-id-type="pmid">24717177</pub-id>
                    <issn>0008-5472</issn> 
                </mixed-citation>
         </ref>
         <ref id="b56">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fusenig</surname>
                     <given-names>NE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Capes-Davis</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bianchini</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sundell</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lichter</surname>
                     <given-names>P</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The need for a worldwide consensus for cell line authentication: experience implementing a mandatory requirement at the International Journal of Cancer</article-title>. 
                    <source>PLoS Biol</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>15</volume>(
                    <issue>4</issue>):
                    <fpage>e2001438</fpage>. 
                    <pub-id pub-id-type="doi">10.1371/journal.pbio.2001438</pub-id>
                    <pub-id pub-id-type="pmid">28414712</pub-id>
                    <issn>1544-9173</issn>
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
